Finex Pulse • Market Signal Briefing

Details	Saved	Published	Title	Source	Tickers
	2025-09-28 16:05 3mo ago	2025-09-28 11:44 3mo ago	Klarna IPO: BNPL Stock or Something Bigger?	stocknewsapi	KLAR
Klarna Group NYSE: KLAR began publicly trading on Sept. 10. Klarna is a global payment provider specializing in buy now, pay later (BNPL) solutions for consumers.
	2025-09-28 16:05 3mo ago	2025-09-28 11:54 3mo ago	ROSEN, A LEADING LAW FIRM, Encourages PubMatic, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PUBM	stocknewsapi	PUBM
NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PubMatic, Inc. (NASDAQ: PUBM) between February 27, 2025 and August 11, 2025, both dates inclusive (the “Class Period”), of the important October 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased PubMatic securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the PubMatic class action, go to https://rosenlegal.com/submit-form/?case_id=43810 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 20, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) a top demand side platform (“DSP”) buyer was shifting a significant number of clients to a new platform which evaluated inventory differently; (2) as a result, PubMatic was seeing a reduction in ad spend and revenue from this top DSP buyer; and (3) as a result of the foregoing, defendants’ positive statements about PubMatic’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the PubMatic class action, go to https://rosenlegal.com/submit-form/?case_id=43810 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com
	2025-09-28 16:05 3mo ago	2025-09-28 12:00 3mo ago	2 More Stocks Riding a Trillion-Dollar Government Spending Spree	stocknewsapi	LAC UURAF
Tom Yeung here with your Sunday Digest. In 2008, Citigroup Inc. (C) was in trouble. The bank had poured billions into mortgage-backed securities, and these complex instruments were now blowing up in their faces. The firm even became the poster child of foolish Wall Street risk-taking after its CEO, Chuck Prince, tried to defend his bank’s actions by quipping, “as long as the music is playing, you’ve got to get up and dance. We’re still dancing.” The U.S. government knew the bank had danced its way into disaster. In October 2008, the U.S. Treasury injected $25 billion into the struggling bank through the taxpayer-funded Troubled Asset Relief Program (TARP). Then in November, they fired their financial bazooka. Under a specially negotiated agreement, the government took a 36% stake in Citigroup in exchange for backing roughly $306 billion in loans and investing over $20 billion in warrants and stock. The massive deal worked. Over the following two years, Citigroup’s finances stabilized and its share price shot back up. The government exited their position in 2010 with $12 billion in profits, and those who hung on would have made 1,000% returns or more. That’s because government support can work wonders. When a well-funded administration pours money into a company with a plan, history tells us to expect success. Consider… Sweden’s saving of Nordbanken in 1992, South Korea’s backing of the Hyundai Group’s takeover of Kia in 1998, And Japan’s rescue of Japan Airlines in 2010. After all, government budgets are massive compared to corporate ones. Official backing also makes it easier for companies to steamroll competition, as Saudi Aramco and China’s “Big 4” banks have done. That’s precisely why InvestorPlace Senior Analyst Louis Navellier is so bullish about Executive Order #14196, a presidential directive that’s set to pour trillions more dollars into American corporations in the coming years. In a series of special reports, he explains why September 30 is shaping up to be a crucial date for that executive order and the U.S. economy, and highlights five stocks he believes are poised to surge 1,000% due to that concurrence of events. You can learn how to access those reports here. I must emphasize that Louis’ timing is crucial. Last week, I introduced four companies primed to receive more government funding. And I was a bit prescient on one of them – Energy Fuels Inc. (UUUU) received a congressional visit last Tuesday. Here is how UUUU and the others have performed this past trading week: Intel Corp. (INTC): +14% Uranium Energy Corp. (UEC): +9% Energy Fuels Inc. (UUUU): +15% Ondas Holdings Inc. (ONDS): +17% However, the window is closing quickly. So, in this update, I’d like to share two more firms that illustrate the power the U.S. government has to become a kingmaker, and why Louis is so concerned about getting in now. America’s Bet on Lithium In July, I wrote about how AI data centers were triggering a resurgence in global lithium prices. These cloud computing sites require enormous amounts of backup power, and their operators have turned to almost every imaginable technology to fill that need. That includes lithium-ion batteries, a technology the Trump administration has historically downplayed. As a result, I recommended shares of Lithium Americas Corp. (LAC). Here’s what I said at the time (highlights added): This mining startup is currently constructing a mine at Thacker Pass, Nevada – one of the world’s largest lithium assets. Once complete, the site could produce 160,000 metric tons of lithium annually – twice as much as Albemarle is allowed to extract from its Chilean assets… Most importantly, Lithium Americas will be a pure play on U.S. lithium production – an industry that could surge as U.S. regulators add tariffs on AI-based metal imports. Since then, the U.S. government has done one better: It’s signaled it may allow a massive $2.26 billion loan to support Lithium Americas’ Thacker Pass mine. Investors previously feared that the Biden-era loan would get canceled by the current administration. In addition, the Trump administration might also seek an equity stake of as much as 10% in Lithium Americas. “Thacker Pass is seen as a linchpin in building a domestic supply chain part of Washington’s long-standing drive to boost U.S. production of lithium,” according to Reuters in its exclusive coverage of the government’s potential investment in LAC. “The project has long been touted by both Republicans and Democrats as a key way to boost U.S. critical minerals production and cut reliance on China, the world’s largest lithium processor.” That would almost guarantee completion of the Thacker Pass mine, since the government would no longer have a financial or political reason to stop the project. Why own 10% of a project that you plan to suspend? That’s already sent shares of LAC up 145% since I recommended it in July. But if history is any guide, that’s likely just the start. Lithium Americas is sitting on one of our country’s most valuable deposits of natural resources. And now the government is showing interest in buying in. So, I’m re-suggesting the stock to those who have not yet invested. The More Speculative Play Over the past several months, China has used its near-monopolistic position in rare earth metals as a bargaining chip in trade negotiations. These essential metals are found in everything from electric motors to LED displays, and a near-ban on Chinese exports last April may have helped bring the U.S. back to the negotiating table. Now, it’s important to know that rare earth materials are not that rare. The most abundant of these, cerium (a metal used in catalytic converters), is as common as copper. Even the rarest of these metals (thulium and lutetium) are more plentiful than gold. In fact, America has at least a half-dozen rare earth mines under development, including: Round Top (Texas) Bear Lodge (Wyoming) Bokan Mountain (Alaska) Elk Creek (Nebraska) La Paz (Arizona) Indeed, shares of rare earth miners have done well following the Trump administration’s $400 million investment in MP Materials Corp. (MP), the company behind California’s Mountain Pass rare earths mine. Not every site has high enough concentrations of rare earths to make mining profitable, so these rare earth miners are still quite valuable. USA Rare Earth Inc. (USAR) has surged 62% since I recommended it in July on the expectation of even more deals. However, the biggest prize of rare earths may come from the processing and separation of these metals. After all, even though there’s more cerium in the earth’s crust than copper, the former is 1,400 times more expensive because its ores are so impure. Miners consider themselves fortunate to find rare earths with more than 4% purity. In addition, most ores contain multiple rare earth elements. Miners require special processing to separate cerium from lanthanum, and so on. It’s a complex operation that requires specialized machinery and know-how that disappeared a decade ago when America’s last rare earths processor closed its doors. In fact, that’s how China keeps such a tight grip on rare earths. Even though the country only mines 60% of the world’s rare earths, its near-90% market share in rare earths processing is why we think of China as the world’s rare earth monopolist. That’s what makes Ucore Rare Metals Inc. (UURAF) so interesting. This early-stage startup is now seeking to bring commercial-scale rare earth separation back to North America. In 2020, Nova Scotia, Canada-based Ucore acquired Innovation Metals Corp., a startup working on a rare earths separation technology called RapidSX. The technology had been successfully tested at the pilot scale, and Ucore was interested in commercializing it in North America. In 2023, they received a $4 million award from the U.S. Department of Defense (DoD) to continue development, followed by another $4 million funding agreement from the Canadian government. Progress has since sped up. In May 2025, Ucore secured an $18.4 million funding agreement with the DoD for the construction of a commercial-scale rare earth processing plant in Louisiana. The site is now in its second phase of construction, and production could begin as soon as mid-2026. That said, there are many “if’s” surrounding Ucore. The company remains dependent on outside funding for now, given its relatively weak balance sheet. There’s also no guarantee that its RapidSX system will produce results at scale… or if the U.S. government will continue to bankroll a company that’s headquartered in Canada. In addition, its primary listing is on the Toronto Stock Exchange, so most investors will find themselves transacting an illiquid over-the-counter version of that stock that’s trading at a massive premium to book values. And so, I am not making UURAF an official recommendation. Nevertheless, investors with access to Canadian markets may want to consider a small investment in this high-potential firm. America’s government has already invested $400 million into MP Materials, a miner with limited processing capacity. And so, it’s not difficult to see the federal government also putting more cash into Ucore, raising a high price tag even further. The Risks of a Government Shutdown Lithium Americas and Ucore are both high-risk plays that depend on government support. They need regulatory approvals to move ahead. It’s the type of risk that not every investor is comfortable with. And if the government shuts down on September 30, that could put a freeze on new federal contracts, sending shares of these risky firms into a spiral. But not every firm receiving federal dollars is so risky. In a recent free presentation, Louis Navellier highlights five firms already posting record profits — companies with the strength to thrive with or without government aid. In fact, a federal shutdown separates the strong from the weak, creating opportunities for investors who position themselves correctly. Click here to watch Louis cover all the details and reveal the free stock recommendation he believes could surge come September 30. Until next week, Thomas Yeung, CFA Market Analyst, InvestorPlace Thomas Yeung is a market analyst and portfolio manager of the Omnia Portfolio, the highest-tier subscription at InvestorPlace. He is the former editor of Tom Yeung’s Profit & Protection, a free e-letter about investing to profit in good times and protecting gains during the bad.
	2025-09-28 16:05 3mo ago	2025-09-28 12:00 3mo ago	Amazon: The Market Isn't Giving Enough Respect To This Behemoth	stocknewsapi	AMZN
Analyst’s Disclosure:I/we have a beneficial long position in the shares of AMZN, NVDA, META, MSFT, GOOGL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
	2025-09-28 16:05 3mo ago	2025-09-28 12:00 3mo ago	UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit	stocknewsapi	UNCY
NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Unicycive securities between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/UNCY. Case Details The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1)Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (2) the OLC NDA's regulatory prospects were likewise overstated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times. What's Next? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/UNCY. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Unicycive you have until October 14, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Follow us for updates on LinkedIn, X, Facebook, or Instagram. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 \| [email protected]
	2025-09-28 16:05 3mo ago	2025-09-28 12:00 3mo ago	SVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit	stocknewsapi	SVRA
NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Savara Inc. (“Savara” or “the Company”) (NASDAQ: SVRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Savara securities between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/SVRA. Case Details The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI BLA lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (3) the foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (4) the delay in MOLBREEVI's regulatory approval increased the likelihood that the Company would need to raise additional capital; and (5) as a result, Defendants' public statements were materially false and misleading at all relevant times. What's Next? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/SVRA. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Savara you have until November 7, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Follow us for updates on LinkedIn, X, Facebook, or Instagram. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 \| [email protected]
	2025-09-28 16:05 3mo ago	2025-09-28 12:00 3mo ago	NUTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Nutex Health Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit	stocknewsapi	NUTX
NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Nutex Health Inc. (“Nutex” or “the Company”) (NASDAQ: NUTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Nutex securities between August 8, 2024 and August 14, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/NUTX. Case Details The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) HaloMD was generating lucrative arbitration outcomes for Nutex by engaging in a coordinated scheme to defraud insurance companies; (2) revenues derived from Nutex’s engagement with HaloMD in the IDR process were unsustainable to the extent they resulted from fraudulent conduct; (3) the Company overstated both the extent to which it had remediated, and its ability to remediate, material weaknesses in its internal controls over financial reporting; (4) as a result, Nutex was unable to account for the treatment of certain stock-based compensation obligations effectively; (5) Nutex improperly classified these stock-based compensation obligations as equity rather than liabilities; (6) the foregoing increased the risk that Nutex would be unable to timely file certain financial reports with the United States Securities and Exchange Commission (“SEC”); (7) accordingly, Nutex’s business and financial prospects were overstated; and (8) as a result, Defendants’ public statements about the Company’s business, operations, and prospects were materially false and misleading at all relevant times. What's Next? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/NUTX. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Nutex you have until October 21, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Follow us for updates on LinkedIn, X, Facebook, or Instagram. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 \| [email protected]
	2025-09-28 16:05 3mo ago	2025-09-28 12:00 3mo ago	CHTR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Charter Communications, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit	stocknewsapi	CHTR
NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Charter Communications, Inc. (“Charter” or “the Company”) (NASDAQ: CHTR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Charter securities between July 26, 2024 and July 24, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/CHTR. Case Details The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Charter was not capable of managing the end of the Affordable Connectivity Program (“ACP”); (2) the ACP’s termination resulted in a sustained decline in internet customers and revenue; (3) the Company had no reasonable basis to assert that it was successfully executing its operations plan or effectively managing the causes of customer declines; and (4) as a result, Defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading at all relevant times. What's Next? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/CHTR. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Charter you have until October 13, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Follow us for updates on LinkedIn, X, Facebook, or Instagram. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 \| [email protected]
	2025-09-28 16:05 3mo ago	2025-09-28 12:00 3mo ago	AI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that C3.ai, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit	stocknewsapi	AI
NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against C3.ai, Inc. (“C3.ai” or “the Company”) (NYSE: AI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired C3.ai securities between February 26, 2025 and August 8, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/AI. Case Details The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) the health of C3.ai’s Chief Executive Officer was materially impairing the Company’s ability to close deals; (2) management was unable or otherwise ineffectual in mitigating the impact of the CEO’s health on business operations; and (3) as a result, C3.ai’s ability to execute on its profit and growth potential was significantly compromised. What's Next? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/AI. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in C3.ai you have until October 21, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Follow us for updates on LinkedIn, X, Facebook, or Instagram. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 \| [email protected]
	2025-09-28 15:05 3mo ago	2025-09-28 10:02 3mo ago	SL Green: More Stable, But Hard To Read Into Its Performance	stocknewsapi	SLG
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
	2025-09-28 15:05 3mo ago	2025-09-28 10:10 3mo ago	Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs	stocknewsapi	BBY BMY CAG EQR KEY KIM KMI LYB MAA MO O OKE PFE PM RF SPG UDR VZ
SummarySeven of the top fifteen Barron's Better Bets (BBB) dividend 'dogs' - including CAG, PFE, VZ, BMY, UDR, KIM, and KEY - are attractively priced for income investors.Analyst forecasts project 17.61% to 34.78% net gains for top-ten BBB dogs by September 2026, with an average estimated gain of 23.96% and lower-than-market volatility.Five of the lowest-priced, highest-yield BBB stocks - CAG, PFE, VZ, BMY, and LYB - are expected to outperform higher-priced peers, offering a 16.89% advantage in projected returns.Investors should focus on BBB stocks where annual dividends from $1,000 invested exceed the share price while monitoring for market pullbacks to achieve fair value.In an interview with Barron’s, Steven Wieting, strategist at Citi Wealth, noted that a growing dividend is a tangible benefit for shareholders and a hallmark of companies with strong balance sheets. "Nobody can fake a dividend," he said.Looking for a portfolio of ideas like this one? Members of The Dividend Dog Catcher get exclusive access to our subscriber-only portfolios. Learn More »victorass88/iStock via Getty Images Foreword While half of this collection of Barron's Better Bets [BBB] is too pricey, or reveals somewhat skinny dividends, seven of the fifteen highest yield Dogs with the "Safest"dividends of the BBB are ready to buy. September finds Conagra ( Analyst’s Disclosure:I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. Recommended For You
	2025-09-28 15:05 3mo ago	2025-09-28 10:13 3mo ago	Vonovia: Recent Underperformance Presents A Buying Opportunity	stocknewsapi	VNNVF VONOY
Analyst’s Disclosure:I/we have a beneficial long position in the shares of VONOY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
	2025-09-28 15:05 3mo ago	2025-09-28 10:15 3mo ago	Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring?	stocknewsapi	LLY
The pharmaceutical company had a clinical setback earlier this year, but that's now in the rearview mirror. Over the past five years, Eli Lilly (LLY 1.43%) has outperformed the broader market, largely thanks to its progress in the GLP-1 arena. Its major breakthroughs in the field are already leading to incredible commercial success. But Lilly isn't done just yet. Recent clinical developments may set the stage for further stock-market gains, and potentially allow the drugmaker to maintain that momentum through the end of the decade. Let's find out what Eli Lilly has been up to, and what that means for investors. The next generation of GLP-1 medicines Eli Lilly's tirzepatide, marketed under the brands Mounjaro for diabetes and Zepbound for weight management, is highly effective -- and generating billions of dollars in sales per quarter already. However, the medicine is administered subcutaneously once a week. This route has several drawbacks compared to oral pills. First, the latter are often cheaper to manufacture. With an oral GLP-1 medicine, drugmakers might be able to pass cost savings onto consumers, making them more accessible than their subcutaneous counterparts. Image source: Getty Images. Second, oral pills are easier on patients who abhor needles and injections. That's why Lilly and other companies in the field have been racing to develop novel oral GLP-1 therapies. There is already one such treatment on the market: Novo Nordisk's Rybelsus, which was first approved in the U.S. in 2019 and is indicated for the treatment of type 2 diabetes. But Eli Lilly is on the verge of launching its own oral option. The company's orforglipron performed well in a series of phase 3 studies in diabetes and obesity. What's more, Lilly recently released results from a 52-week study in diabetes patients that pitted orforglipron and Rybelsus head-to-head. During the trial, the highest dose of orforglipron resulted in an average blood-sugar reduction of 1.9%, compared to 1.5% for Rybelsus. Additionally, orforglipron induced an average weight loss of 8.2%, versus 5.3% for Rybelsus. Once again, Lilly is showing its dominance in this area, even against the company with a first-mover advantage. And if orforglipron is approved by year-end, Eli Lilly's shares could soar. Although the pharmaceutical giant has yet to complete regulatory submissions for orforglipron, some Wall Street analysts believe that the medicine is an excellent candidate for a new program launched by the U.S. Food and Drug Administration, which reduces the 10-month review time for drug applications to a mere one or two months. Is Lilly overvalued? No one would question that Eli Lilly is performing extremely well. In the past couple of years, it has arguably produced more positive clinical data in the rapidly growing field of weight management than the rest of the industry combined. And the drugmaker is reaping the rewards of a job well done; its financial results speak for themselves. Second-quarter revenue jumped by 38% year over year to $15.6 billion, while non-GAAP (adjusted) net earnings per share grew 61% to $6.31. Lilly even increased its guidance for the full year 2025. However, the stock was recently trading at 24.7 times forward earnings estimates, while the average for the healthcare industry is 16.5. That said, Eli Lilly is worth a hefty premium. Its revenue and earnings are already growing faster than those of its peers. And there are good reasons to believe the pharmaceutical leader will keep that up through the next few years (at the very least), as it continues to benefit from its groundbreaking work in the GLP-1 market. According to some analysts, orforglipron could generate as much as $12.7 billion in revenue by 2030. Will this medicine cannibalize sales from Lilly's other GLP-1 products? Not at all. Tirzepatide is still growing strongly and could generate nearly $62 billion in revenue by 2030, a figure unheard-of in the industry. A few years ago, some analysts predicted that tirzepatide would peak at $25 billion, which would have been pretty impressive. It's already set to eclipse that number this year, just three years after it first hit the market. Lilly's success in the GLP-1 market has been remarkable and should continue driving solid top-line growth. Furthermore, several other products will contribute. Lilly's Alzheimer's disease medicine Kisunla has grabbed barely any headlines, but it could also achieve blockbuster status, as could Ebglyss, a new treatment for eczema. Eli Lilly's outstanding results and prospects justify its valuation, leaving plenty of upside for the company. The stock might not soar based on the recent clinical trial data for orforglipron showing its superiority to Rybelsus unless it leads to regulatory approval by year-end. But Lilly still looks likely to deliver market-beating returns over the next five years.
	2025-09-28 15:05 3mo ago	2025-09-28 10:15 3mo ago	This stock is showing striking similar movements to Palantir; Time to buy?	stocknewsapi	SNOW
Palantir Technologies (NASDAQ: PLTR) built its reputation on years of base-building before staging an explosive rally, fueled by growing demand for its government and enterprise AI platforms. That consolidation phase set the stage for one of the most dramatic moves in recent technology history, with the stock hitting multiple highs in recent months. As of press time, PLTR shares were trading at $177.57, up 136% year-to-date. Now, data from charting platform TrendSpider suggests that Snowflake (NYSE: SNOW) may be tracing a similar path. While its share price has traded sideways since its IPO, revenue has continued to grow steadily quarter after quarter, mirroring Palantir’s pre-breakout pattern. PLTR and SNOW price chart. Source: TrendSpider With data emerging as the backbone of AI adoption, the parallels raise the question: could Snowflake be the next Palantir? PLTR and SNOW stock fundamentals Palantir’s momentum has been driven by a string of high-profile contracts that expand its dominance in AI-enabled defense and government work. The company recently secured a $10 billion U.S. Army contract, signed a major partnership with Boeing’s defense unit, and saw NATO adopt its Maven Smart System, all underscoring its role as a critical AI provider in security and defense. Snowflake, meanwhile, is broadening its platform beyond data warehousing into full AI infrastructure. The company is acquiring Crunchy Data to strengthen its PostgreSQL and AI app development capabilities, positioning it to compete more directly with Databricks. It has also partnered with Salesforce, dbt Labs, and others on the Open Semantic Interchange initiative, aimed at making enterprise data more interoperable for AI applications. Leadership changes are also underway. In this case, longtime CFO Mike Scarpelli recently stepped down after overseeing a $3 billion share buyback, a move seen as a vote of confidence in Snowflake’s long-term value. At the same time, institutional investors have been quietly increasing their stakes, reflecting renewed optimism in the company’s growth trajectory. Overall, Snowflake’s chart mirrors Palantir’s pre-breakout phase, but while PLTR is already benefiting from major defense contracts, Snowflake is still building its foundation to become an AI-first enterprise platform. Featured image via Shutterstock
	2025-09-28 15:05 3mo ago	2025-09-28 10:17 3mo ago	Mid-America Apartment: Near 52-Week Low Is A Buying Opportunity	stocknewsapi	MAA
SummaryMid-America Apartment Communities is attractively valued near its 52-week low, offering a 4.4% dividend yield and strong fundamentals.MAA benefits from favorable Sunbelt migration trends, stable occupancy, and robust rent collections.MAA's disciplined development, high-return renovations, and A- rated balance sheet support long-term value creation and income growth.I rate MAA as a solid 'Buy,' expecting potential total returns of 10-13% annually as supply normalizes and fundamentals remain resilient.Looking for a portfolio of ideas like this one? Members of iREIT®+HOYA Capital get exclusive access to our subscriber-only portfolios. Learn More » Daniel Grizelj/DigitalVision via Getty Images Nearly every industry on the market today bears cyclicality, and that’s what makes it possible for patient value investors to capture outsized gains over the long run. This holds especially true for dividend stocks, whose yields go Analyst’s Disclosure:I/we have a beneficial long position in the shares of MAA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I am not an investment advisor. This article is for informational purposes and does not constitute as financial advice. Readers are encouraged and expected to perform due diligence and draw their own conclusions prior to making any investment decisions. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. Recommended For You
	2025-09-28 15:05 3mo ago	2025-09-28 10:22 3mo ago	Meta Debuts Next-Gen AI Glasses—A Turning Point for Reality Labs?	stocknewsapi	META
Meta Platforms Today $743.75 -5.16 (-0.69%) As of 09/26/2025 04:00 PM Eastern 52-Week Range$479.80▼ $796.25Dividend Yield0.28% P/E Ratio26.93 Price Target$826.05 Meta Platforms NASDAQ: META recently held one of its biggest events each year: Meta Connect. At this event, the company takes the opportunity to unveil its latest innovations when it comes to consumer devices. This year, Meta released the next generation of its artificial intelligence (AI) glasses: the Meta Ray-Ban Display. With this device, Mark Zuckerberg may have moved closer to his goal of AI glasses eventually replacing smartphones. However, for investors, what could the Meta Ray-Ban Display mean for the tech stock in the short and long term? Could it be a breakthrough for Meta’s Reality Labs segment? Let’s break down this new device and its potential implications for the stock below. Get Meta Platforms alerts: Meta Ray-Ban Display: Huge Advancements, Strong Reviews Right off the bat, it’s clear that the Meta Ray-Ban Display is a significant upgrade over the company’s past AI glasses. This comes, as the device’s name would suggest; it includes a visual display. Wearers can interact with a two-dimensional display in the right lens. Users can now operate the device more discreetly with a visible interface, reducing the need to speak and enabling easier public use. Wearers can use the display to send and receive messages on WhatsApp, Messenger, and Instagram, and access a map that provides turn-by-turn walking directions. They can also now see a preview of the picture or video they want to capture. Before, capturing images with the Ray-Ban glasses was somewhat of a guessing game. Meta says this image previewing feature was the number one request it received from users of the previous device. The device can also provide subtitles and translate foreign languages when speaking to another person. Despite these considerable advancements, the most interesting feature of the device is how wearers interact with the display. With the glasses comes a wristband called the Meta Neural Band. The band reads electric impulses from the user's arm to detect hand gestures corresponding to different controls. Early reviews of the device have been generally very positive, with Engadget’s Karissa Bell saying it "feels like the beginning of the kind of smart glasses a lot of people have been waiting for." Strong Adoption Could Alter Investor Outlook on Reality Labs With this new tech, Meta seems to have taken a big step forward in its mission to one day replace smartphones with AI glasses. Still, it can’t do nearly as much as a smartphone, and the number of applications users can access is very small. Thus, the Meta Ray-Ban Display doesn’t make the firm any type of real threat to Apple NASDAQ: AAPL at this point. However, the device can add upside to Meta's shares. Compared to past Meta glasses, the visual display is much more aligned with what smartphones offer. Thus, they provide a tangible and early demonstration of a product that, with further advancements, could compete significantly with smartphones. Meta Platforms Stock Forecast Today12-Month Stock Price Forecast: $826.05 11.06% Upside Moderate Buy Based on 47 Analyst Ratings Current Price$743.75High Forecast$980.00Average Forecast$826.05Low Forecast$600.00Meta Platforms Stock Forecast Details If sales are strong, the prospect of widespread adoption of AI glasses in the future becomes more realistic, as consumers show they are open to this potential future. Seeing this positively shift sentiment on Reality Labs wouldn't be overly surprising. So far, many have viewed the segment as a nuisance on Meta’s income statement, tolerated due to its impressive advertising business. The success of the Meta Ray-Ban Display could change this view, positioning Reality Labs as a business with a more verifiable chance of long-term success. This could create positive near-to-mid-term price action in Meta shares when data on the device’s sales comes out. However, if adoption is weak, an opposite reaction could also occur. Still, Reality Labs has been losing over $3 billion a quarter for at least two years. Nonetheless, Meta shares have soared over that time, showing that markets aren’t holding this against the company much. AI Glasses Continue to Add Long-Term Upside Potential Longer term, the rapid advancement of Meta’s AI glasses continues to support the notion that Meta could one day become a worldwide leader in AI hardware. Its current place as a leader in social media and AI advertising makes it a difficult company to bet against. Whether its latest device will be a breakthrough for Reality Labs remains in question, but the bullish outlook for the stock continues until something significant changes. Should You Invest $1,000 in Meta Platforms Right Now?Before you consider Meta Platforms, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Meta Platforms wasn't on the list. While Meta Platforms currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report
	2025-09-28 15:05 3mo ago	2025-09-28 10:30 3mo ago	5 Dividend Powerhouses Every Investor Should Own	stocknewsapi	JPM LMT NVDA PG XOM
From defense contracts to AI chips, these dividend giants dominate their industries while rewarding shareholders with growing cash distributions. Forget chasing the next hype-fueled stock. Real wealth comes from companies that dominate essential industries and return cash to shareholders year after year. These dividend powerhouses span consumer goods, defense, energy, and finance, with records of resilience through recessions, wars, and market crashes. The formula is simple: durable businesses, consistent cash flows, and dividends that continue to rise. The beauty is boring predictability -- exactly what long-term investors should want. Image source: Getty Images. The defense dividend fortress Lockheed Martin (LMT 0.66%) yields 2.7% with support from one of the most reliable customers in the world: the U.S. government. Its flagship F-35 fighter program is slated to run into the 2070s, providing decades of predictable revenue that have fueled 6.6% annual dividend growth over the past five years. While its 73% payout ratio looks elevated, it is supported by an $886 billion U.S. defense budget and record global military spending. With geopolitical tensions from Ukraine to Taiwan driving defense outlays higher, Lockheed offers one of the most secure dividends investors can find. The consumer staples cash machine Procter & Gamble (PG 0.21%) yields about 2.8% and owns some of the world's most essential consumer brands -- Tide, Pampers, Gillette, Crest -- generating durable demand across economic cycles. The company has paid a dividend every year since 1890 (134 consecutive years) and has raised it for nearly seven decades. With 6% average dividend growth over five years and a forward payout ratio in the low 60s, P&G is a textbook example of steady income compounded over time. Its strong brand power and ability to raise prices in inflationary periods provide a buffer, letting P&G maintain margins when input costs rise. The energy income giant ExxonMobil (XOM 1.35%) offers a 3.4% yield that looks attractive in an era when many investors discount traditional energy stocks due to transition fears. Dividend growth has averaged just 2.6% annually over the past five years, but a 56% payout ratio leaves room for steady increases as oil demand remains resilient. The Pioneer acquisition cemented Exxon's dominance in the Permian Basin, while massive offshore Guyana discoveries provide decades of low-cost production. Add in the stability of its chemicals and refining operations, and with industrywide capital discipline replacing past drilling excesses, Exxon's dividend looks increasingly sustainable. The AI growth paradox Nvidia (NVDA 0.27%) sports an almost invisible 0.02% yield, but that misses the point entirely. The real story: 20% annual dividend growth over five years from a minuscule 1.1% payout ratio. This isn't an income play today -- it's tomorrow's dividend champion being born. With artificial intelligence (AI) demand creating unprecedented pricing power and a gross margin above 70%, Nvidia could multiply its dividend 50-fold and barely notice. Buying for current yield would be foolish, but ignoring the dividend growth potential would be equally shortsighted. The banking profit printer JPMorgan Chase (JPM 0.83%) yields 1.9% with reliability, growing its dividend 8% annually over five years while maintaining a conservative 27.2% payout ratio. CEO Jamie Dimon built a fortress balance sheet that survived the regional banking crisis without breaking a sweat. The bank's diversified revenue streams -- from investment banking to wealth management to credit cards -- provide stability through any rate cycle. With the conservative payout ratio leaving massive room for increases and the business model proven resilient through multiple economic shocks, JPMorgan's dividend growth looks set to continue regardless of Federal Reserve policy. The dividend diversification playbook These five stocks create a perfectly balanced dividend portfolio. ExxonMobil and P&G provide immediate income at 3.4% and 2.8% yields. Lockheed and JPMorgan offer steady growth with defensive characteristics. Nvidia represents the moonshot -- negligible current income but potentially explosive future payouts. Together they span defense, consumer goods, energy, technology, and financials -- sectors that rarely crash simultaneously. Average the yields and you get 2.2%, but focus on the payout ratios, averaging just 46%, and you see the real opportunity: massive dividend growth ahead. JPMorgan Chase is an advertising partner of Motley Fool Money. George Budwell has positions in JPMorgan Chase, Lockheed Martin, and Nvidia. The Motley Fool has positions in and recommends JPMorgan Chase and Nvidia. The Motley Fool recommends Lockheed Martin. The Motley Fool has a disclosure policy.
	2025-09-28 15:05 3mo ago	2025-09-28 10:40 3mo ago	Euphoric Valuation Takes The Shine Off Rheinmetall AG's Solid Fundamentals	stocknewsapi	RNMBF RNMBY
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
	2025-09-28 15:05 3mo ago	2025-09-28 10:40 3mo ago	How To Survive A 30% Market Crash In Retirement	stocknewsapi	BAM DB ENB NEE PM SCHD SPY VOO
SummarySequence of return risk can devastate retirement portfolios, especially when early negative returns coincide with withdrawals, undermining the traditional 4% rule.Dividend investing offers a powerful solution by providing steady cash flows that are largely independent of market volatility, neutralizing sequence risk.Building a portfolio of high-quality, dividend-growing stocks can deliver superior returns and reduce stress.Following a disciplined approach of buying undervalued dividend stocks and selling when overvalued ensures income growth, portfolio resilience, and protection against inflation.Looking for a helping hand in the market? Members of The Dividend Freedom Tribe get exclusive ideas and guidance to navigate any climate. Learn More » Arsgera/iStock via Getty Images Written by Sam Kovacs Introduction Retiring just before a market crash will wreak havoc in a retirement portfolio. This danger is well documented and researched. It is referred to as "sequence of return" risk: it's the risk that the Analyst’s Disclosure:I/we have a beneficial long position in the shares of PM, ENB, NEE, BAM, DB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. Recommended For You
	2025-09-28 15:05 3mo ago	2025-09-28 10:46 3mo ago	These 3 Dividend ETFs Pay Monthly, But Also Have Big Upside Potential	stocknewsapi	DIA PFF PGX
Creating passive income streams can take many forms. Investors can choose from a plethora of stocks, bonds, alternative assets (such as real estate) and other less-traditional options (including crypto, etc.
	2025-09-28 15:05 3mo ago	2025-09-28 10:54 3mo ago	CHTR ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Class Action Lawsuit Against Charter Communications, Inc. (CHTR)	stocknewsapi	CHTR
, /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Charter Communications, Inc. ("Charter") (NASDAQ: CHTR) on behalf of those who purchased or otherwise acquired Charter securities, including purchasers of call options, or sellers of put options, between July 26, 2024, and July 24, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is October 14, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Charter losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/charter-communications-inc?utm_source=PR_Newswire&mktm=PR You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at[email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the impact of the cancelation of the Affordable Connectivity Program ("ACP") was a material event Charter was unable to manage or promptly move beyond; (2) the ACP end was actually having a sustaining impact on Internet customer declines and revenue; (3) Charter was not executing broader operations in a way that would compensate for, or overcome the impact, of the ACP ending; (4) the Internet customer declines and broader failure of Charter's execution strategy created much greater risks on business plans and earnings growth than reported; (5) accordingly, Charter had no reasonable basis to state the company was successfully executing operations, managing causes of Internet customer declines, or provide overly optimistic statements about the long term trajectory of Charter and its EBITDA growth; and (6) as a result, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/MvQfxMhmwQY THE LEAD PLAINTIFF PROCESS: Charter investors may, no later than October 14, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Charter investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/charter-communications-inc?utm_source=PR_Newswire&mktm=PR ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com. CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 15:05 3mo ago	2025-09-28 10:55 3mo ago	Why Teradyne Is a Core Play in the AI Hardware Boom	stocknewsapi	TER
Teradyne Today $135.31 +2.44 (+1.84%) As of 09/26/2025 04:00 PM Eastern 52-Week Range$65.77▼ $144.16Dividend Yield0.35% P/E Ratio46.82 Price Target$118.63 A recent jump in Teradyne's NASDAQ: TER stock, which saw it climb over 12% in a single trading session, has caught the market's attention. Such a move is significant for a company with a market capitalization of $21 billion. It begs the question: Why is a company specializing in semiconductor test equipment suddenly demonstrating such strong momentum? A closer look reveals this is not a momentary spike but a market awakening to a deeper reality: Teradyne has become an indispensable and foundational player in the artificial intelligence (AI) revolution. While much of the focus in the AI space is on high-profile chip designers, the success of the entire industry rests on the ability to produce incredibly complex hardware that works flawlessly. This is where Teradyne provides its value. The company operates as a classic picks and shovels play, supplying the essential tools needed to ensure the gold rush in AI hardware pays off. The recent stock performance suggests that investors are beginning to fully understand and appreciate the value of the one selling the tools. Forging the Tools for the AI Era The primary force behind Teradyne's renewed momentum is AI hardware's explosive growth and complexity. As AI models become more sophisticated, the chips that power them are evolving into technological marvels of unprecedented density and complexity. This creates a critical challenge for manufacturers: ensuring quality and yield. The cost of a single defect in a multi-thousand-dollar AI accelerator is enormous, making rigorous testing a crucial quality control step and an economic necessity. This is where demand for Teradyne's advanced equipment is igniting. On the company's second quarter 2025 earnings call, CEO Greg Smith confirmed this shift, stating that he expects AI compute to be the dominant driver of the core Semiconductor Test business for the rest of the year. The company is backing this strategy with targeted innovation. Its recently launched Magnum 7H memory tester is a prime example. This system is purpose-built to handle the unique challenges of testing High Bandwidth Memory (HBM), the ultra-fast memory stacked directly onto high-performance AI GPUs. With the Magnum 7H already shipping to major HBM manufacturers, Teradyne has a direct line to profit from every new AI server that gets built. This is further supported by strategic moves, such as the acquisition of Quantifi Photonics, which bolsters its position in testing another critical AI component: silicon photonics. Where Teradyne’s Strategy Meets the Bottom Line This strategic positioning in the AI supply chain is already translating into solid financial performance. While second-quarter revenue was down year-over-year, a reflection of residual weakness in consumer and automotive markets, the company's forward guidance signals a powerful, AI-driven rebound is underway. Key financial metrics highlight this turning point: Beating Expectations: For Q2 2025, Teradyne reported revenue of $651.8 million and non-GAAP earnings per share (EPS) of $0.57, comfortably surpassing analyst estimates. Strong Forward Guidance: For Q3 2025, management projects revenue to land between $710 million and $770 million. At the midpoint, this represents a powerful 14% sequential growth rate, giving concrete financial weight to management's optimism. Profitability and Valuation: The company's non-GAAP operating profit was 15.1% in the second quarter and is projected to expand to 19.5% at the midpoint of Q3 guidance. With a trailing price-to-earnings ratio (P/E) of approximately 46, the stock is valued for its growth potential, which upcoming quarters are forecast to deliver. Shareholder Returns: This financial strength supports healthy shareholder returns, including a consistent quarterly dividend of $0.12 per share and an active share repurchase program, which removed $119 million of stock from the market in the second quarter alone. Wall Street's Re-rating Begins Teradyne Stock Forecast Today12-Month Stock Price Forecast: $118.63 -12.33% Downside Moderate Buy Based on 18 Analyst Ratings Current Price$135.31High Forecast$200.00Average Forecast$118.63Low Forecast$85.00Teradyne Stock Forecast Details Following the stock's recent ascent, investors are asking what comes next. A review of Wall Street activity suggests that a reevaluation is in its early stages. According to data from 18 analysts, Teradyne holds a Moderate Buy consensus rating. While its average price target of $118.63 sits below the current trading price, older targets weigh down this figure. The most recent analyst revisions, however, show a decidedly bullish trend. For example, Susquehanna recently boosted its price target to $200, citing AI-driven opportunities. This type of revision suggests that some analysts are actively re-rating the stock's potential as the AI growth story becomes clearer. The breakdown of 11 Buy ratings, 5 Hold ratings, and 2 Sell ratings suggests that positive sentiment is strong, despite the consensus target still falling short of the stock's recent price action. A Core Holding for the AI Infrastructure Buildout Teradyne's recent surge is more than just a momentary market reaction; it reflects a fundamental shift in its business. The company's deep-seated expertise in testing complex electronics has placed it at the center of a generation's most significant technological transition. As the buildout of AI infrastructure continues, the demand for more complex and powerful chips will only grow. With it, the need for the critical testing technology that Teradyne provides will become even more pronounced. For investors seeking a foundational way to participate in the AI megatrend, Teradyne is moving beyond its cyclical semiconductor identity and emerging as a secular growth story, making it a compelling consideration for any technology-focused portfolio. Should You Invest $1,000 in Teradyne Right Now?Before you consider Teradyne, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teradyne wasn't on the list. While Teradyne currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation. Get This Free Report
	2025-09-28 15:05 3mo ago	2025-09-28 11:00 3mo ago	DOW Investors: October 28, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP	stocknewsapi	DOW
, /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Dow Inc. ("Dow") (NYSE: DOW) on behalf of those who purchased or otherwise acquired Dow securities between January 30, 2025, and July 23, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is October 28, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Dow losses, you may CLICK HERE or copy and paste the following link into your browser:https://www.ktmc.com/new-cases/dow-inc?utm_source=PR_Newswire&mktm=PR You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Dow's ability to mitigate macroeconomic and tariff-related headwinds, as well as to maintain the financial flexibility needed to support its lucrative dividend, was overstated; (2) the true scope and severity of the foregoing headwinds' negative impacts on Dow's business and financial condition was understated, particularly with respect to competitive and pricing pressures, softening global sales, and demand for Dow's products, as well as an oversupply of products in Dow's global markets; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times. Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/41CEzLbyvm0 THE LEAD PLAINTIFF PROCESS: Dow investors may, no later than October 28, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Dow investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/dow-inc?utm_source=PR_Newswire&mktm=PR ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com. CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Snap, Inc. of Class Action Lawsuit and Upcoming Deadlines - SNAP	stocknewsapi	SNAP
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Snap, Inc. ("Snap" or the "Company") (NYSE: SNAP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Snap and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until October 20, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Snap securities during the Class Period. A copy of the Complaint can be obtained a t www.pomerantzlaw.com . [Click here for information about joining the class action] On August 5, 2025, Snap announced its financial results for the second quarter of fiscal year 2025, disclosing a deceleration in advertising revenue growth. The Company attributed the slowdown to "an issue related to our ad platform, the timing of Ramadan, and the effects of the de minimis changes." On this news, Snap's stock price fell $1.61 per share, or 17.15%, to close at $7.78 per share on August 6, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amer Sports, Inc. - AS	stocknewsapi	AS
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amer Sports, Inc. ("Amer" or the "Company") (NYSE: AS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Amer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On September 19, 2025, Amer's flagship brand Arc'teryx conducted a promotional fireworks display in Tibet, prompting a backlash from environmentalists and triggering an investigation by Chinese authorities. Amer's stock price subsequently fell $2.18 per share, or 5.82%, to close at $35.27 per share on September 22, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO	stocknewsapi	SLNO
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Soleno and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 15, 2025, Scorpion Capital ("Scorpion") published a report that described Soleno's only product, Vykat XR, as overpriced and potentially unsafe for children. Following publication of the Scorpion report, Soleno's stock price fell $5.73 per share, or 7.41%, to close at $71.63 per share on August 15, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skillz Inc.- SKLZ	stocknewsapi	SKLZ
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skillz Inc. ("Skillz" or the "Company") (NYSE: SKLZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Skillz and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On September 2, 2025, Skillz disclosed in a filing with the U.S. Securities and Exchange Commission that Tether Studios and its affiliate Tether Games (together, "Tether") plan to terminate all agreements with Skillz, effective September 1, 2025. Under the agreements, Skillz has licensed its software to Tether for use in monetizing Tether's games. In return, both companies share the revenue from user entry fees. After receiving the notice, Skillz filed a lawsuit on September 1, 2025, seeking to block Tether's termination of their agreements. Skillz is also disputing Tether's reasons for ending the deal. On this news, Skillz's stock price fell $1.50 per share, or 17.22%, to close at $7.21 per share on September 3, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innovative Solutions and Support, Inc. - ISSC	stocknewsapi	ISSC
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Innovative Solutions and Support, Inc. ("IS&S" or the "Company") (NASDAQ: ISSC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether IS&S and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 14, 2025, IS&S issued a press release announcing its financial results for its fiscal third quarter of 2025. Therein, the Company's Chief Executive Officer Shahram Askarpour advised, among other things, that a "pull-forward of F-16 production into the current quarter . . . will impact revenue over the next two quarters[.]" On this news, IS&S's stock price fell $6.22 per share, or 31.53%, to close at $13.51 per share on August 14, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CPI Card Group Inc. - PMTS	stocknewsapi	PMTS
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CPI Card Group Inc. ("CPI" or the "Company") (NASDAQ: PMTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether CPI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 8, 2025, CPI announced second quarter 2025 financial results that missed top-line and bottom-line estimates. Among other items, CPI reported a GAAP earnings-per-share figure of $0.04 per share, missing estimates by $0.46, and revenue of $129.75M, missing estimates by $3.21M. In addition, the Company updated its outlook for 2025, stating that it expects net sales in low double-digit to mid-teens growth, compared to the prior outlook of mid-to-high single-digit growth. CPI stated that the change from the prior outlook reflects the addition of Arroweye Solutions, Inc.—an on-demand payment card solutions provider acquired by CPI in May 2025—partially offset by the negative impact of the accounting change for revenue recognition timing of work-in-process orders. On this news, CPI's stock price fell $5.37 per share, or 28.83%, to close at $13.25 per share on August 8, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	Pomerantz Law Firm Announces the Filing of a Class Action Against CTO Realty Growth, Inc. and Certain Officers - CTO	stocknewsapi	CTO
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against CTO Realty Growth, Inc. ("CTO" or the "Company") (NYSE: CTO) and certain officers. The class action, filed in the United States District Court for the Middle District of Florida, and docketed under 25-cv-01516, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired CTO securities between February 18, 2021 and June 24, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. If you are an investor who purchased or otherwise acquired CTO securities during the Class Period, you have until October 7, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] CTO is a publicly traded real estate investment trust ("REIT") that owns and operates a portfolio of purported high-quality, retail-based properties located primarily in higher growth markets in the United States ("U.S."). The Company converted into a REIT in February 2021 and, as of December 31, 2024, owned 23 income properties in seven states, including Ashford Lane, a retail and dining center in Atlanta, Georgia. Under guidelines established by the U.S. Securities and Exchange Commission ("SEC"), REITs must pay out at least 90% of their taxable profits to shareholders annually as dividends. In return, REIT companies are exempt from most corporate income tax. CTO has touted that its operation as a REIT "provides the tax-efficient organizational structure for [its] stockholders" that "will allow [it] to provide them with an attractive and sustainable dividend." To measure its performance, CTO uses the financial metric Adjusted Funds from Operations ("AFFO"). The AFFO of a REIT, though subject to varying methods of computation, is generally equal to the REIT's funds from operations with adjustments made for recurring capital expenditures (also referred to as "capex") used to maintain the quality of the REIT's underlying assets. Professional analysts tend to prefer AFFO because it takes into consideration additional costs incurred by the REIT as well as additional income sources, such as rent increases. Thus, analysts believe that AFFO provides for a more accurate base number when estimating present values and a better predictor of the REIT's future ability to pay dividends. The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) CTO's dividends were less sustainable than Defendants had led investors to believe; (ii) the Company used deceptive and unsustainable practices to artificially inflate its AFFO and overstate the true profitability of its Ashford Lane property; (iii) accordingly, CTO's business and/or financial prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times. On June 25, 2025, Wolfpack Research ("Wolfpack") published a report entitled "CTO: The B. Riley of REITs" (the "Wolfpack Report" or the "Report"), which compared CTO unfavorably to B. Riley, a financial services company that recently lost more than 90% of its value amid three years of losses, soured investments, delayed financial reports and revelations that the SEC had been investigating whether the firm gave shareholders an accurate picture of its health. Citing interviews with former employees and whistleblowers, the Wolfpack Report accused CTO of, among other things, "not generat[ing] enough cash to pay its recurring capex and cover its dividends since converting to a REIT in 2021" and instead "rel[ying] on dilution (increasing shares outstanding by 70% since December 2022) to cover a $38 million dividend shortfall from 2021 to 2024," employing a "manipulative definition of [AFFO] where they exclude recurring capex, unlike all of their self-identified shopping center REIT peers," and "us[ing] a sham loan to hide the collapse of a top tenant from shareholders at Ashford Lane." (Emphasis in original). Further, Wolfpack predicted imminent further dilution of the Company, noting that CTO has just $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million per quarter, along with approximately $12 million in additional planned capital expenditures. On this news, CTO's stock price fell $0.98 per share, or 5.42%, to close at $17.10 per share on June 25, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	Pomerantz Law Firm Announces the Filing of a Class Action Against Tesla, Inc. and Certain Officers - TSLA	stocknewsapi	TSLA
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tesla, Inc. ("Tesla" or the "Company") (NASDAQ: TSLA) and certain officers. The class action, filed in the United States District Court for the Western District of Texas, and docketed under 25-cv-01213, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Tesla securities between April 19, 2023 and June 22, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. If you are an investor who purchased or otherwise acquired Tesla securities during the Class Period, you have until October 4, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Tesla designs, develops, manufactures, leases, and sells electric vehicles and autonomous driving vehicles, as well as energy generation and storage systems, in the United States ("U.S."), China, and internationally. The Company offers certain advanced driver assist systems in its vehicles under its Autopilot and Full Self-Driving (Supervised) options which purportedly "intelligently and accurately complete [] driving maneuvers for you [i.e., the driver], including route navigation, steering, lane changes, parking and more under your active supervision." In April 2022, at an event celebrating the opening of the Company's Gigafactory Texas global headquarters and manufacturing facility, Tesla's Chief Executive Officer Defendant Elon Musk announced that the Company would be building a vehicle dedicated for use as a robotaxi (the "Robotaxi"). Tesla has touted its Robotaxi business as a "ride-hailing network that will eventually operate fully autonomous vehicles" and has stated that "[w]e expect this business will open access to a new customer base even as modes of transportation evolve. We believe our capabilities and advancements in [artificial intelligence], including the deployment of Cortex, our training cluster at Gigafactory Texas, differentiates us from our competitors." The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Tesla overstated the effectiveness of its autonomous driving technology; (ii) there was thus a significant risk that the Company's autonomous driving vehicles, including the Robotaxi, would operate dangerously and/or in violation of traffic laws; (iii) the foregoing increased the likelihood that Tesla would become subject to heightened regulatory scrutiny; (iv) accordingly, Tesla's business and/or financial prospects were overstated; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times. On June 22, 2025, Tesla debuted its Robotaxi service with a highly publicized launch event in Austin, Texas. At the event, approximately 10 autonomous driving Robotaxis with a "safety monitor" in the front passenger seat began picking up invite-only passengers in a geofenced 10-mile by five-mile square of Austin. The next day, Bloomberg published an article entitled "Tesla Robotaxi Videos Show Speeding, Driving Into Wrong Lane," which reported that "Tesla Inc.'s self-driving taxis appeared to violate traffic laws during the company's first day offering paid rides, with one customer capturing footage of a left turn gone wrong and others traveling in cars that exceeded posted speed limits." That same day, in an article entitled "Tesla Robotaxi Incidents Draw Scrutiny From US Safety Agency," Bloomberg reported that the U.S. National Highway Traffic Safety Administration ("NHTSA") had contacted Tesla regarding the foregoing incidents, noting that the NHTSA "is aware of the incidents that were captured in videos posted on social media and is gathering additional information from the company." Further, the Bloomberg article quoted a statement released by the agency that "[f]ollowing an assessment of those reports and other relevant information, NHTSA will take any necessary actions to protect road safety." Then on June 24, 2025, in an article entitled "NHTSA Now Targets Tesla Robotaxi After Autonomous EVs Break Traffic Laws," International Business Times stated, in relevant part, that "the emergence of videos showing concerning behaviour by Tesla's robotaxis may dampen public enthusiasm. The controversy has also triggered fresh criticism and could impact the scheduled rollout later this month." Following these reports, Tesla's stock price fell $21.13 per share over two trading sessions, or 6.05%, to close at $327.55 per share on June 25, 2025. After the end of the Class Period, on August 1, 2025, it was reported that a jury in a trial in the U.S. District Court for the Southern District of Florida determined that Tesla should be held partly liable for a fatal 2019 Autopilot crash, and must compensate the family of the deceased and an injured survivor a portion of $329 million in damages. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Coty Inc. - COTY	stocknewsapi	COTY
NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Coty Inc. ("Coty" or the "Company") (NYSE: COTY).
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN	stocknewsapi	AXGN
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Axogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 25, 2025, Axogen issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025." On this news, Axogen's stock price fell $1.47 per share, or 9.04%, to close at $14.79 per share on August 25, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR	stocknewsapi	JSPR
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08010, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. If you are an investor who purchased or otherwise acquired Jasper securities during the Class Period, you have until November 18, 2025 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  [Click here for information about joining the class action] Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible Urticaria ("CIndU"), and Asthma. The Company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor ("SCF") from binding to and signaling through the CD117 ("c-Kit") receptor on mast and stem cells. According to Jasper, the "SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s] that blocking this pathway may lead to depletion of these cells throughout the body, including in the lungs and in the skin, which could lead to significant clinical benefit for patients with mast-cell driven diseases such as asthma and chronic urticarias" and "[t]o that end, [Jasper is] focusing on advancing a portfolio of clinical programs in mast cell driven diseases." In 2024, to "strengthen [its] balance sheet and support development of briquilimab," Jasper completed an oversubscribed $50 million financing "with a syndicate of leading life science investors," purportedly "extending [its] cash runway through the third quarter of 2025." In November 2023, the Company commenced a Phase 1b/2a clinical study of subcutaneous briquilimab for the treatment of CSU (the "BEACON Study"). When announcing the first patient dosing in the BEACON Study, Jasper's Chief Executive Officer Defendant Ronald Martell stated, in relevant part, that he was "confident in the ability of our clinical organization to continue to execute at a high level as we advance briquilimab into clinical trials in CIndU and other mast cell-driven diseases." In December 2024, the Company commenced a Phase 1b/2a clinical study evaluating briquilimab in allergic asthma (the "ETESIAN Study"). In addition, Jasper has attempted to develop briquilimab as a one-time conditioning therapy for severe combined immunodeficiency ("SCID") patients undergoing a second stem cell transplant. Under the Drug Supply Chain Security Act —a law enacted by Congress in 2013 designed to improve and ensure the safety of the U.S pharmaceutical supply chain—all prescription drugs must be labeled with a unique product identifier that includes, among other things, a "lot number." Drug "lots" are batches of a product that are manufactured, processed, packaged, or stored under the same conditions. If a medication is compromised, pharmaceuticals companies can use lot numbers to trace the affected batches and alert healthcare providers. According to the Company, "[t]he manufacture of pharmaceuticals is subject to extensive [current Good Manufacturing Practices ("cGMP")] regulations, which impose various procedural and documentation requirements and govern all areas of record keeping, production processes and controls, personnel and quality control." Because Jasper does not currently own or operate any manufacturing facility, the Company relies on third-party contract manufacturing organizations to produce its drug candidates in purported "accordance with cGMP regulations for use in [its] clinical studies." The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times. On July 7, 2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed with drug from the lot in question," that "[t]he Company is investigating the drug product lot in question and expects to have the results of that investigation in the coming weeks," and that Jasper was "taking steps to ensure that drug product from the lot in question is returned to the Company and that sites have drug product from other lots to continue dosing." Further, the press release revealed that the Company "has also determined that the drug product lot in question was used to treat participants enrolled in the ETESIAN [Study]. As a result, and in order to focus resources on advancing briquilimab in CSU, the Company is halting the study and pausing development in asthma." Finally, the press release stated that "the Company is halting development in SCID" and, contrary to its prior representation of having a strong balance sheet and a cash runway extending "through the third quarter of 2025," that Jasper "will be implementing a number of other cost cutting measures including a potential restructuring, to extend runway and reduce expenses." On this news, Jasper's stock price fell $3.73 per share, or 55.1%, to close at $3.04 per share on July 7, 2025. Market analysts were quick to comment on the Company's announcement. For example, on July 7, 2025, BMO Capital Markets published a report downgrading Jasper to market perform and lowering its price target from $6.77 per share to $4.00 per share (the "BMO Report"). The BMO Report stated, in relevant part, that "potential Briquilimab drug lot issues, coupled with existing uncertainty around dose-response [], will pressure the [Jasper] story moving forward" given, among other things, Jasper's "financing overhang" and market competition. After the end of the Class Period, on July 9, 2025, the Company issued a press release entitled "Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway." The press release revealed that Jasper was reducing its workforce by approximately 50%, that "[i]n order to focus resources on the development of briquilimab in chronic urticaria, Jasper is halting its other clinical and preclinical programs," and that Defendant Edwin Tucker was departing his role as the Company's Chief Medical Officer effective August 1, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising.  Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	Pomerantz Law Firm Announces the Filing of a Class Action Against Fluor Corporation and Certain Officers - FLR	stocknewsapi	FLR
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fluor Corporation ("Fluor" or the "Company") (NYSE: FLR) and certain officers. The class action, filed in the United States District Court for the Northern District of Texas, Dallas Division, and docketed under 25-cv-02496, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fluor securities between February 18, 2025 and July 31, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. If you are an investor who purchased or otherwise acquired Fluor securities during the Class Period, you have until November 14, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Fluor provides engineering, procurement, and construction ("EPC"), fabrication and modularization, and project management services worldwide. The Company operates through three segments: Urban Solutions, Energy Solutions, and Mission Solutions. Throughout 2024 and the first quarter of 2025, Fluor's Urban Solutions segment accounted for the largest portion of the Company's revenue and profit. The Urban Solutions segment offers EPC and project management services to the advanced technologies and manufacturing, life sciences, mining and metals, and infrastructure industries, as well as provides professional staffing services. The Company's infrastructure projects in this segment include work on, inter alia, the Gordie Howe International Bridge ("Gordie Howe"), as well as the Interstate 365 Lyndon B. Johnson ("I-635/LBJ") and Interstate 35E ("I-35") highways in Texas. In February 2025, Fluor provided financial guidance for the full year ("FY") of 2025, including adjusted EBITDA of $575 million to $675 million and adjusted earnings per share ("EPS") of $2.25 per share to $2.75 per share. Defendants reaffirmed the foregoing financial guidance in May 2025, notwithstanding their acknowledgement of the potential negative impacts of ongoing economic uncertainty on Fluor's business resulting from trade tensions and other market conditions. Contemporaneously, Defendants touted, inter alia, the purported health and stability of Fluor's and its customers' operations and the strength of the Company's risk mitigation strategy, both for itself and its clients. The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Fluor's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) costs associated with the Gordie Howe, I-635/LBJ, and I-35 projects were growing because of, inter alia, subcontractor design errors, price increases, and scheduling delays; (ii) the foregoing, as well as customer reduction in capital spending and client hesitation around economic uncertainty, was having, or was likely to have, a significant negative impact on the Company's business and financial results; (iv) accordingly, Fluor's financial guidance for FY 2025 was unreliable and/or unrealistic, the effectiveness of the Company's risk mitigation strategy was overstated, and the impact of economic uncertainty on the Company's business and financial results was understated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times. On August 1, 2025, Fluor issued a press release reporting its financial results for the second quarter ("Q2") of 2025. Among other results, the press release reported Q2 non-GAAP EPS of $0.43, missing consensus estimates by $0.13, and revenue of $3.98 billion, representing a 5.9% year-over-year decline and missing consensus estimates by $570 million. Defendants blamed these disappointing results on, inter alia, growing costs in multiple infrastructure projects due to subcontractor design errors, price increases, and scheduling delays, as well as reduced capital spending by customers. The same press release also provided a negatively revised financial outlook for FY 2025, guiding to adjusted EBITDA of $475 million to $525 million, down significantly from Defendants' prior guidance of $575 million to $675 million, and adjusted EPS of $1.95 per share to $2.15 per share, down significantly from Defendants' prior guidance of $2.25 per share to $2.75 per share, citing "client hesitation around economic uncertainty and its impact on new awards and project delays and results for the quarter[.]" The same day, Fluor hosted a conference call with investors and analysts to discuss the Company's Q2 2025 financial results. During that call, the Company's Chief Executive Officer, Defendant James R. Breuer, disclosed that the infrastructure projects that had negatively impacted Fluor's Q2 2025 results were the Gordie Howe, I-635/LBJ, and I-35 projects. Following the foregoing disclosures, Fluor's stock price fell $15.35 per share, or 27.04%, to close at $41.42 per share on August 1, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lesaka Technologies, Inc. - LSAK	stocknewsapi	LSAK
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lesaka Technologies, Inc. ("Lesaka" or the "Company") (NASDAQ: LSAK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Lesaka and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On September 10, 2025, Lesaka disclosed in a filing with the U.S. Securities and Exchange Commission ("SEC") that the Audit Committee of its Board of Directors had "concluded that the Company's unaudited condensed consolidated financial statements for the quarters ended September 30, 2024, December 31, 2024, and March 31, 2025, respectively, included in the Company's Quarterly Reports on Form 10-Q for the quarters ended September 30, 2024, December 31, 2024, and March 31, 2025, respectively (the "Quarterly Reports"), should be restated, and that such unaudited condensed financial statements should no longer be relied upon, due to the Company's re-evaluation of the classification of certain revenue that has been reported as an agent rather than as principal, and related cost of goods sold." On this news, Lesaka's stock price fell $0.48 per share, or 10.15%, to close at $4.25 per share on September 11, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediaAlpha, Inc. - MAX	stocknewsapi	MAX
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediaAlpha, Inc. ("MediaAlpha" or the "Company") (NYSE: MAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether MediaAlpha and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On June 24, 2024, Wolfpack Research published a report entitled "MAX: Our Investigation Reveals MAX Is Participating in Consumer Fraud." In pertinent part, Wolfpack announced that it was "short the insurance lead generator, MediaAlpha, Inc. (NYSE: MAX) following our research into the company's [Health Insurance] segment[.]" Wolfpack stated that it believed "[MediaAlpha] uses dishonest and sometimes outright fraudulent ads along with deceptive websites to trick consumers into providing their personal information in exchange for a health insurance 'quote.' [MediaAlpha] then sells this information as raw lead data or uses it to generate clicks or calls for its lead-buying partners. Our investigation indicates as much as 78% of [MediaAlpha's] Health [Insurance] lead-buying partners are running boiler room health insurance scams or are flagrantly violating laws concerning telemarketing." On this news, MediaAlpha's stock price fell $1.92 per share, or 11.84%, over the following two trading sessions, to close at $14.29 per share on June 25, 2024. Then, on November 4, 2024, MediaAlpha disclosed receipt of a letter from the Federal Trade Commission ("FTC") staff stating that the FTC staff was "prepared to recommend the filing of a complaint against the Company," claiming that MediaAlpha falsely "represented itself as affiliated with government entities, made misleading claims (in particular regarding health insurance products and use of consumers' personal information) and utilized deceptive advertising." On this news, MediaAlpha's stock price fell $4.46 per share, of 27.7%, to close at $11.62 per share on November 5, 2024. Then, on August 6, 2025, MediaAlpha announced it was settling claims with the FTC for $45 million. According to the FTC's complaint, MediaAlpha would use advertisements and websites claiming to provide health insurance quotes to collect information from consumers looking for insurance, while in reality, MediaAlpha sold nothing to consumers, and the consumer information it collected would be sold to telemarketers. According to the FTC, MediaAlpha sold approximately 119 million leads about consumers in 2024 alone. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Freeport-McMoran Inc. - FCX	stocknewsapi	FCX
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Freeport-McMoran Inc. ("Freeport" or the "Company") (NYSE: FCX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Freeport and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On September 9, 2025, Freeport issued a press release announcing the suspension of mining activities at its Grasberg Block Cave operation in Indonesia, after "a large flow of wet material from a production drawpoint . . . blocked access to certain areas within the mine," trapping seven workers. On this news, Freeport's stock price fell $2.80 per share, or 5.99%, to close at $43.87 per share on September 9, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RCI Hospitality Holdings, Inc. - RICK	stocknewsapi	RICK
NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RCI Hospitality Holdings, Inc. ("RCI" or the "Company") (NASDAQ: RICK).
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO	stocknewsapi	NVO
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Novo Nordisk and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until September 30, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Novo Nordisk securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com . [Click here for information about joining the class action] On July 29, 2025, Novo Nordisk significantly lowered its sales outlook for 2025. The Company attributed the reduction to "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition." On this news, Novo Nordisk's American Depositary Receipt ("ADR") price fell $15.06 per ADR, or 21.83%, to close at $53.94 per ADR on July 29, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tronox Holdings Plc of Class Action Lawsuit and Upcoming Deadlines - TROX	stocknewsapi	TROX
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tronox Holdings Plc ("Tronox" or the "Company") (NYSE: TROX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Tronox and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until November 3, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Tronox securities during the Class Period. A copy of the Complaint can be obtained a t www.pomerantzlaw.com . [Click here for information about joining the class action] On July 30, 2025, Tronox announced its financial results for the second quarter of fiscal 2025, revealing a significant reduction in sales of the Company's TiO2 products for the quarter. The Company attributed the decline to "softer than anticipated coatings season and heightened competitive dynamics." As a result of the setback in sales, Tronox revised its 2025 financial outlook, lowering its full-year revenue guidance and reducing its dividend by 60%. On this news, Tronox's stock price fell $1.95 per share, or 37.94%, to close at $3.19 per share on July 31, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in SelectQuote, Inc. of Class Action Lawsuit and Upcoming Deadlines - SLQT	stocknewsapi	SLQT
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against SelectQuote, Inc. ("SelectQuote" or the "Company") (NYSE: SLQT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether SelectQuote and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until October 10, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired SelectQuote securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com . [Click here for information about joining the class action] On May 1, 2025, the U.S. Department of Justice ("DOJ") filed a False Claims Act complaint against SelectQuote, alleging "[f]rom 2016 through at least 2021" SelectQuote received "tens of millions of dollars" in "illegal kickbacks" from health insurance companies in exchange for steering Medicare beneficiaries to enroll in the insurers' plans. Further, according to the DOJ, SelectQuote, in exchange for kickbacks, engaged in a conspiracy with major insurers to illegally discriminate against beneficiaries deemed to be less profitable, including those with disabilities. The DOJ concluded that SelectQuote made materially false claims by stating it offers "unbiased coverage comparisons" when in fact it "repeatedly directed Medicare beneficiaries to the plans offered by insurers that paid them the most money, regardless of the quality or suitability of the insurers' plans." On this news, SelectQuote's stock price fell $0.61 per share, or 19.24%, to close at $2.56 per share on May 1, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lineage, Inc.- LINE	stocknewsapi	LINE
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lineage, Inc. ("Lineage" or the "Company") (NASDAQ: LINE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Lineage and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On or around July 25, 2024, Lineage conducted its initial public offering of 56,882,051 shares of common stock priced at $78.00 per share. Then, on April 30, 2025, Lineage reported its financial results for the first quarter of 2025. Among other items, Lineage reported that its total revenue had decreased by 2.7% to $1.29 billion for the quarter, stating that it "experienced more normal seasonal trends in the first quarter after multiple years of elevated inventory levels." On this news, Lineage's stock price fell $8.26 per share, or 14.62%, to close at $48.23 per share on April 30, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Fly-E Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - FLYE	stocknewsapi	FLYE
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fly-E Group, Inc. ("Fly-E" or the "Company") (NASDAQ: FLYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Fly-E and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until November 7, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Fly-E securities during the Class Period. A copy of the Complaint can be obtained a t www.pomerantzlaw.com . [Click here for information about joining the class action] On August 14, 2025, Fly-E filed a form NT 10-Q: Notification of inability to timely file Form 10-Q for the first quarter of fiscal year 2026 revealing a substantial decrease of 32% in net revenues "primarily driven by a decrease in total units sold." In pertinent part, the Company attributed the decline to "recent lithium-battery accidents involving E-Bikes and E-Scooters." On this news, Fly-E's stock price fell $6.76 per share, or 87.11%, to close at $1.00 per share on August 15, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines - CYTK	stocknewsapi	CYTK
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate ("Cytokinetics" or the "Company") (NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Cytokinetics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until November 17, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Cytokinetics securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com .         [Click here for information about joining the class action] On March 10, 2025, Cytokinetics disclosed that the U.S. Food and Drug Administration ("FDA") had decided not to convene an advisory committee meeting to review the Company's New Drug Application ("NDA") for aficamten. On May 1, 2025, Cytokinetics announced that the FDA had extended the Prescription Drug User Fee Act action date for aficamten's NDA from September 26, 2025 to December 26, 2025 in order to review a Risk Evaluation and Mitigation Strategy ("REMS") submitted at the FDA's request after the initial NDA filing, thereby disclosing that the Company had not included a REMS in the original NDA. On this news, Cytokinetics' stock price fell $5.57 per share, or 12.98%, to close at $37.35 per share on May 2, 2025. Then, on May 6, 2025, Chief Executive Officer Robert I. Blum acknowledged that Cytokinetics had multiple pre-NDA meetings with the FDA to discuss safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. On this news, Cytokinetics' stock price fell $2.70 per share, or 7.36%, to close at $33.97 per share on May 6, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising.  Prior results do not guarantee similar outcomes.    CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Lantheus Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - LNTH	stocknewsapi	LNTH
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Lantheus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until November 10, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Lantheus securities during the Class Period. A copy of the Complaint can be obtained a t www.pomerantzlaw.com . [Click here for information about joining the class action] On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025, which fell short of market expectations. Lantheus announced, among other items, that sales of its radiopharmaceutical oncology product Pylarify had decreased year-over-year due to an alleged "temporal competitive disruption." The Company further reduced its previous full-year projections due to Pylarify's shortfall. On this news, Lantheus's stock price fell $24.35 per share, or 23.23%, to close at $80.49 per share on May 7, 2025. Then, on August 6, 2026, Lantheus announced disappointing second quarter 2025 results, revealing earnings-per-share ("EPS") and revenue figures that missed expectations. Once again, Lantheus significantly lowered growth expectations for Pylarify, sales of which had fallen 8.3% year-over-year, and further lowered the Company's full-year 2025 projections. Lantheus attributed its results in part to ongoing competition, which impacted Pylarify's pricing dynamics. On this news, Lantheus's stock price fell $20.76 per share, or 28.58%, to close at $51.87 per share on August 6, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	Pomerantz Law Firm Announces the Filing of a Class Action Against Dow Inc. and Certain Officers - DOW	stocknewsapi	DOW
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Dow Inc. ("Dow" or the "Company") (NYSE: DOW) and certain officers. The class action, filed in the United States District Court for the Eastern District of Michigan, Northern Division, and docketed under 25-cv-12744, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Dow securities between January 30, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. If you are an investor who purchased or otherwise acquired Dow securities during the Class Period, you have until October 28, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Dow is an American materials science company, serving customers in the packaging, infrastructure, mobility, and consumer applications industries. Dow conducts its worldwide operations through six global businesses organized into three operating segments: (i) Packaging & Specialty Plastics, (ii) Industrial Intermediates & Infrastructure, and (iii) Performance Materials & Coatings. Historically, Dow has touted its "industry-leading dividend," which is of particular importance to investors. On conference calls with investors and analysts, Dow's Chief Executive Officer, Defendant Jim Fitterling ("Fitterling"), has variously stated that the Company's "dividend is a key element of our investment thesis," and that "north of 65% of our owners count on that dividend." Notwithstanding an ongoing slump in the materials science industry, as well as the recent onset of tariff-related market uncertainties, at all relevant times, Defendants represented that Dow was well positioned to weather macroeconomic and tariff-related headwinds while maintaining sufficient levels of financial flexibility to support the Company's lucrative dividend. Specifically, Defendants cited various purported strengths and advantages unique to Dow in its industry, including, inter alia, the Company's purported "differentiated portfolio," "cost-advantaged footprint," and "industry-leading flexibility to navigate global trade dynamics." Throughout the Class Period, Defendants made materially false and misleading statements regarding Dow's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Dow's ability to mitigate macroeconomic and tariff-related headwinds, as well as to maintain the financial flexibility needed to support its lucrative dividend, was overstated; (ii) the true scope and severity of the foregoing headwinds' negative impacts on Dow's business and financial condition was understated, particularly with respect to competitive and pricing pressures, softening global sales and demand for the Company's products, and an oversupply of products in the Company's global markets; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times. On June 23, 2025, BMO Capital downgraded its recommendation on Dow to "Underperform" from "Market Perform" while also cutting its price target on the Company's stock to $22.00 per share from $29.00 per share, citing sustained weakness across key end markets and mounting pressure on the Company's dividend. On this news, Dow's stock price fell $0.89 per share, or 3.21%, to close at $26.87 per share on June 23, 2025. Then, on July 24, 2025, Dow issued a press release reporting its financial results for the second quarter of 2025. Therein, Dow reported a non-GAAP loss per share of $0.42, significantly larger than the approximate $0.17 to $0.18 per share loss expected by analysts. Dow also reported net sales of $10.1 billion, representing a 7.3% year-over-year decline and missing consensus estimates by $130 million, "reflecting declines in all operating segments." The Company further reported, inter alia, that "[s]equentially, net sales were down 3%, as seasonally higher demand in Performance Materials & Coatings was more than offset by declines across the other operating segments." Defendant Fitterling blamed these disappointing results on "the lower-for-longer earnings environment that our industry is facing, amplified by recent trade and tariff uncertainties," while providing a dour outlook marked by "signs of oversupply from newer market entrants who are exporting to various regions at anti-competitive economics." In a separate press release issued the same day, Dow revealed that it was cutting its dividend in half, from $0.70 per share to only $0.35 per share, citing the need for "financial flexibility amidst a persistently challenging macroeconomic environment." Following these disclosures, Dow's stock price fell $5.30 per share, or 17.45%, to close at $25.07 per share on July 24, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 14:05 3mo ago	2025-09-28 10:00 3mo ago	Pomerantz Law Firm Announces the Filing of a Class Action Against Nutex Health Inc. and Certain Officers - NUTX	stocknewsapi	NUTX
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nutex Health Inc. ("Nutex" or the "Company") (NASDAQ: NUTX) and certain officers. The class action, filed in the United States District Court for the Southern District of Texas, and docketed under 25-cv- 03999, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nutex securities between August 8, 2024 and August 14, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. If you are an investor who purchased or otherwise acquired Nutex securities during the Class Period, you have until October 21, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Nutex is a physician-led, healthcare services and operations company that began publicly trading via a reverse merger in April 2022. The Company operates through three divisions: a hospital division comprised of 24 hospital facilities in 11 states, a population health management division, and real estate. Nutex generally operates as an out-of-‎network provider and generates revenue, in part, from contracts with patients and, in most cases, a third-party payor such as commercial insurance, workers compensation insurance or, in limited cases, Medicare or Medicaid. According to Nutex, on average, greater than 90% of its net patient service revenue is paid by third-party payors. Prior to 2022, if a patient with health insurance received care from an out-of-network provider, even unknowingly, the patient's health plan might not have covered the entire out-of-network cost, leaving the patient with higher costs than if the care had come from an in-network provider. In addition to any out-of-network cost sharing the patient might have owed, the out-of-network provider could bill the patient for the difference between the billed charge and the amount the patient's health plan paid, unless banned by state law—a practice called "balance billing". An unexpected balance bill from an out-of-network provider is frequently referred to as a "surprise bill". In December 2020, to curb surprise out-of-network billing, Congress enacted the No Surprises Act ("NSA"). The NSA, which took effect January 1, 2022, requires private health plans to cover out-of-network claims and apply in-network cost sharing, and prohibits doctors, hospitals, and other covered providers from billing patients more than the in-network cost sharing amount for surprise medical bills. In addition, the NSA established an independent dispute resolution ("IDR") process to determine out-of-network payment amounts between health plans and providers when open negotiations fail to result in an agreed-upon payment amount. In the IDR process, the provider and health plan each submit a proposed payment amount and ‎‎additional information supporting their payment offers to an arbitrator, a certified IDR entity. The arbitrator must select one of the two proposed payment amounts, taking into ‎account the ‎‎"qualifying payment amount" ("QPA")—the median contract rate for like specialties in the same geographical market—and additional circumstances including, among other things, the level of training, outcomes ‎‎measurements of the facility, the acuity of the individual treated, and the case mix and scope of services of the ‎facility ‎providing the service. Initially, as an out-of-network provider, Nutex's business suffered after the NSA went into effect. Specifically, because cost sharing under the statute is generally based on the median in-network rate a health plan pays for a service, the NSA prevented Nutex from charging patients higher prices for its services through out-of-network billing. Indeed, in March 2023, Nutex reported that "[s]ince the NSA became effective [. . .] our average payment by insurers of patient claims for emergency services has declined by approximately 30% including as much as a 37% reduction for physician services." The Company stated that, "[i]n our experience, insurers often initially pay amounts lower than the QPA without regard for other information relevant to the claim. This requires us to make appeals using the IDR process." In response, in July 2024, the Company engaged with HaloMD, a "third-party IDR vendor," to "assist in the recovery of certain out of network claims" in the IDR process. While Nutex did not disclose the identity of its third-party IDR vendor to investors at that time, the Company shortly thereafter began to tout the success of its "arbitration strategy" in increasing its revenues. For example, in August 2024, Nutex stated that it "believe[s] [] there is a lot of potential incremental value and revenue to be gained from arbitration" and "[i]n recent articles and public data, we are seeing that providers are prevailing 70% to 80% of the time in arbitration." Then, in March 2025, announcing its fourth quarter and full year 2024 results, Nutex reported that "[t]otal revenue increased $232.3 million to $479.9 million for the year ended December 31, 2024" and that "[t]he arbitration process resulted in approximately $169.7 million more in revenue in 2024 than in 2023, which amounted to approximately 73.1% of the $232.3 million revenue increase." At all relevant times, the Company has identified material weaknesses in its internal control over financial reporting. Specifically, Nutex has acknowledged that it had "[i]neffective design, implementation, and operation controls over logical access, program change management, and vendor management controls," that "[b]usiness process controls across all financial reporting processes were not effectively designed and implemented to properly address the risk of material misstatement, including controls without proper segregation of duties between preparer and reviewer and key management review controls," and "[i]neffective design and implementation of controls over the completeness and accuracy of information included in key spreadsheets supporting the financial statements." However, Nutex has consistently represented that it has "started the process of designing and implementing effective internal control measures to remediate the reported material weaknesses." The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iv) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (v) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (vi) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the United States Securities and Exchange Commission ("SEC"); (vii) accordingly, Nutex's business and/or financial prospects were overstated; and (viii) as a result, Defendants' public statements were materially false and misleading at all relevant times. On July 22, 2025, Blue Orca Capital ("Blue Orca") issued a short report on Nutex (the "Blue Orca Report" or the "Report"). The Blue Orca Report alleged, among other things, that "HaloMD achieved dramatically lucrative results for clients like Nutex by engaging in a coordinated fraudulent scheme to steal millions of dollars from insurance companies on behalf of and in conjunction with its healthcare billing clients." Specifically, Blue Orca referenced three recent "[b]ombshell [l]awsuits" filed against HaloMD. The lawsuits, brought variously by Blue Cross Blue Shield Healthcare Plan of Georgia, Inc., Community Insurance Company d/b/a Anthem Blue Cross and Blue Shield, and Anthem Blue Cross Life and Health Insurance Company and Blue Cross of California d/b/a Anthem Blue Cross, allege that HaloMD violated various federal and state laws by submitting false attestations of eligibility and initiating massive volumes of IDR disputes. As summarized by Blue Orca, the plaintiffs in these lawsuits accused HaloMD and its clients of "flooding the arbitration system with thousands of claims that they knew at the time of submission to be ineligible" and alleging that HaloMD was able to garner improper payments by "falsely attesting to the eligibility of claims and [. . .] improperly inflating payment offers that far exceeded the amounts to which providers should have been entitled." Accordingly, Blue Orca concluded that "it may just be a matter of time before another suit is filed against HaloMD, this time including Nutex," and "[o]nce Nutex can no longer use the NSA arbitration system to receive unsustainably high reimbursement rates, our suspicion is that Nutex will return to penny stock status." Following publication of the Blue Orca Report, Nutex's stock price fell $11.18 per share, or 10.05%, to close at $100.01 per share on July 22, 2025. On July 24, 2025, Nutex issued a press release responding to the Blue Orca Report, stating that it "strongly disagrees with the allegations in the report" and that it "expects to provide related updates in its upcoming earnings release and Form 10-Q for the second quarter of 2025 due on or before August 14, 2025." However, after the market closed on August 14, 2025, Nutex announced that it would "delay filing its Form 10-Q for the period ending June 30, 2025", citing "non-cash accounting adjustments related to the treatment of stock-based compensation obligations for certain under-construction and ramping hospitals, as disclosed in previous filings." When Nutex failed to rebut the allegations of the Blue Orca Report, the Company's stock price fell $18.22 per share, or 16.39%, to close at $92.91 per share on August 15, 2025. After the end of the Class Period, on August 21, 2025, Nutex filed a Current Report on Form 8-K with the SEC which, among other things, contained a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard and stated that the Audit Committee of the Company's Board of Directors concluded that certain of the Company's previously issued financial statements "treated non-cash obligations related to under-construction and ramping hospitals as equity rather than liabilities and should be restated." This filing also purported to address the Blue Orca Report. However, Nutex merely provided a generalized description of the arbitration process under the NSA and the Company's own claims process, acknowledged that Nutex had engaged HaloMD to assist in the IDR process, and discussed two of the three recent lawsuits filed against HaloMD, noting that the Company had not been named as a Defendant. As such, Nutex's filing did not in fact meaningfully rebut any of the allegations contained in the Blue Orca Report. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In
	2025-09-28 13:05 3mo ago	2025-09-28 07:30 3mo ago	Latam Insights: Venezuela Embraces USDT, OranjeBTC Rises in Brazil	cryptonews	USDT
Welcome to Latam Insights, a compilation of the most relevant crypto news from Latin America over the past week. In this week's edition: Venezuela moves its internal disbursements to USDT, OranjeBTC surges as Latam's largest bitcoin treasury company, and Argentina negotiates $20 billion lifeline with the U.S.
	2025-09-28 13:05 3mo ago	2025-09-28 07:30 3mo ago	Hyperliquid's HyperDrive DeFi Loses $773K in Account Compromise, Funds Bridged to BNB Chain and Ethereum	cryptonews	BNB ETH HYPE
HyperDrive DeFi protocol suffered a $773,000 exploit affecting two accounts in its Treasury Bill market with stolen funds split between BNB Chain and Ethereum networks through bridge transfers, as the attacker exploited an arbitrary call vulnerability in the router contract stealing 672,934 USDT0 and 110,244 thBILL tokens.

Saved

Published

Title

Source

Tickers

2025-09-28 16:05 3mo ago

2025-09-28 11:44 3mo ago

Klarna IPO: BNPL Stock or Something Bigger?

stocknewsapi

KLAR

Klarna Group NYSE: KLAR began publicly trading on Sept. 10. Klarna is a global payment provider specializing in buy now, pay later (BNPL) solutions for consumers.

2025-09-28 16:05 3mo ago

2025-09-28 11:54 3mo ago

ROSEN, A LEADING LAW FIRM, Encourages PubMatic, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PUBM

stocknewsapi

PUBM

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PubMatic, Inc. (NASDAQ: PUBM) between February 27, 2025 and August 11, 2025, both dates inclusive (the “Class Period”), of the important October 20, 2025 lead plaintiff deadline.

SO WHAT: If you purchased PubMatic securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the PubMatic class action, go to https://rosenlegal.com/submit-form/?case_id=43810 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 20, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) a top demand side platform (“DSP”) buyer was shifting a significant number of clients to a new platform which evaluated inventory differently; (2) as a result, PubMatic was seeing a reduction in ad spend and revenue from this top DSP buyer; and (3) as a result of the foregoing, defendants’ positive statements about PubMatic’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the PubMatic class action, go to https://rosenlegal.com/submit-form/?case_id=43810 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

2025-09-28 16:05 3mo ago

2025-09-28 12:00 3mo ago

2 More Stocks Riding a Trillion-Dollar Government Spending Spree

stocknewsapi

LAC UURAF

Tom Yeung here with your Sunday Digest.

In 2008, Citigroup Inc. (C) was in trouble.

The bank had poured billions into mortgage-backed securities, and these complex instruments were now blowing up in their faces. The firm even became the poster child of foolish Wall Street risk-taking after its CEO, Chuck Prince, tried to defend his bank’s actions by quipping, “as long as the music is playing, you’ve got to get up and dance. We’re still dancing.”

The U.S. government knew the bank had danced its way into disaster. In October 2008, the U.S. Treasury injected $25 billion into the struggling bank through the taxpayer-funded Troubled Asset Relief Program (TARP). Then in November, they fired their financial bazooka.

Under a specially negotiated agreement, the government took a 36% stake in Citigroup in exchange for backing roughly $306 billion in loans and investing over $20 billion in warrants and stock.

The massive deal worked.

Over the following two years, Citigroup’s finances stabilized and its share price shot back up. The government exited their position in 2010 with $12 billion in profits, and those who hung on would have made 1,000% returns or more.

That’s because government support can work wonders. When a well-funded administration pours money into a company with a plan, history tells us to expect success.

Consider…

Sweden’s saving of Nordbanken in 1992,
South Korea’s backing of the Hyundai Group’s takeover of Kia in 1998,
And Japan’s rescue of Japan Airlines in 2010.

After all, government budgets are massive compared to corporate ones. Official backing also makes it easier for companies to steamroll competition, as Saudi Aramco and China’s “Big 4” banks have done.

That’s precisely why InvestorPlace Senior Analyst Louis Navellier is so bullish about Executive Order #14196, a presidential directive that’s set to pour trillions more dollars into American corporations in the coming years. In a series of special reports, he explains why September 30 is shaping up to be a crucial date for that executive order and the U.S. economy, and highlights five stocks he believes are poised to surge 1,000% due to that concurrence of events.

You can learn how to access those reports here.

I must emphasize that Louis’ timing is crucial. Last week, I introduced four companies primed to receive more government funding. And I was a bit prescient on one of them – Energy Fuels Inc. (UUUU) received a congressional visit last Tuesday.

Here is how UUUU and the others have performed this past trading week:

Intel Corp. (INTC): +14%
Uranium Energy Corp. (UEC): +9%
Energy Fuels Inc. (UUUU): +15%
Ondas Holdings Inc. (ONDS): +17%

However, the window is closing quickly. So, in this update, I’d like to share two more firms that illustrate the power the U.S. government has to become a kingmaker, and why Louis is so concerned about getting in now.

America’s Bet on Lithium
In July, I wrote about how AI data centers were triggering a resurgence in global lithium prices. These cloud computing sites require enormous amounts of backup power, and their operators have turned to almost every imaginable technology to fill that need. That includes lithium-ion batteries, a technology the Trump administration has historically downplayed.

As a result, I recommended shares of Lithium Americas Corp. (LAC). Here’s what I said at the time (highlights added):

This mining startup is currently constructing a mine at Thacker Pass, Nevada – one of the world’s largest lithium assets. Once complete, the site could produce 160,000 metric tons of lithium annually – twice as much as Albemarle is allowed to extract from its Chilean assets…

Most importantly, Lithium Americas will be a pure play on U.S. lithium production – an industry that could surge as U.S. regulators add tariffs on AI-based metal imports.

Since then, the U.S. government has done one better: It’s signaled it may allow a massive $2.26 billion loan to support Lithium Americas’ Thacker Pass mine. Investors previously feared that the Biden-era loan would get canceled by the current administration.

In addition, the Trump administration might also seek an equity stake of as much as 10% in Lithium Americas.

“Thacker Pass is seen as a linchpin in building a domestic supply chain part of Washington’s long-standing drive to boost U.S. production of lithium,” according to Reuters in its exclusive coverage of the government’s potential investment in LAC. “The project has long been touted by both Republicans and Democrats as a key way to boost U.S. critical minerals production and cut reliance on China, the world’s largest lithium processor.”

That would almost guarantee completion of the Thacker Pass mine, since the government would no longer have a financial or political reason to stop the project. Why own 10% of a project that you plan to suspend?

That’s already sent shares of LAC up 145% since I recommended it in July. But if history is any guide, that’s likely just the start. Lithium Americas is sitting on one of our country’s most valuable deposits of natural resources. And now the government is showing interest in buying in.

So, I’m re-suggesting the stock to those who have not yet invested.

The More Speculative Play
Over the past several months, China has used its near-monopolistic position in rare earth metals as a bargaining chip in trade negotiations. These essential metals are found in everything from electric motors to LED displays, and a near-ban on Chinese exports last April may have helped bring the U.S. back to the negotiating table.

Now, it’s important to know that rare earth materials are not that rare. The most abundant of these, cerium (a metal used in catalytic converters), is as common as copper. Even the rarest of these metals (thulium and lutetium) are more plentiful than gold.

In fact, America has at least a half-dozen rare earth mines under development, including:

Round Top (Texas)
Bear Lodge (Wyoming)
Bokan Mountain (Alaska)
Elk Creek (Nebraska)
La Paz (Arizona)

Indeed, shares of rare earth miners have done well following the Trump administration’s $400 million investment in MP Materials Corp. (MP), the company behind California’s Mountain Pass rare earths mine. Not every site has high enough concentrations of rare earths to make mining profitable, so these rare earth miners are still quite valuable. USA Rare Earth Inc. (USAR) has surged 62% since I recommended it in July on the expectation of even more deals.

However, the biggest prize of rare earths may come from the processing and separation of these metals. After all, even though there’s more cerium in the earth’s crust than copper, the former is 1,400 times more expensive because its ores are so impure. Miners consider themselves fortunate to find rare earths with more than 4% purity.

In addition, most ores contain multiple rare earth elements. Miners require special processing to separate cerium from lanthanum, and so on. It’s a complex operation that requires specialized machinery and know-how that disappeared a decade ago when America’s last rare earths processor closed its doors.

In fact, that’s how China keeps such a tight grip on rare earths. Even though the country only mines 60% of the world’s rare earths, its near-90% market share in rare earths processing is why we think of China as the world’s rare earth monopolist.

That’s what makes Ucore Rare Metals Inc. (UURAF) so interesting. This early-stage startup is now seeking to bring commercial-scale rare earth separation back to North America.

In 2020, Nova Scotia, Canada-based Ucore acquired Innovation Metals Corp., a startup working on a rare earths separation technology called RapidSX. The technology had been successfully tested at the pilot scale, and Ucore was interested in commercializing it in North America. In 2023, they received a $4 million award from the U.S. Department of Defense (DoD) to continue development, followed by another $4 million funding agreement from the Canadian government.

Progress has since sped up. In May 2025, Ucore secured an $18.4 million funding agreement with the DoD for the construction of a commercial-scale rare earth processing plant in Louisiana. The site is now in its second phase of construction, and production could begin as soon as mid-2026.

That said, there are many “if’s” surrounding Ucore. The company remains dependent on outside funding for now, given its relatively weak balance sheet. There’s also no guarantee that its RapidSX system will produce results at scale… or if the U.S. government will continue to bankroll a company that’s headquartered in Canada.

In addition, its primary listing is on the Toronto Stock Exchange, so most investors will find themselves transacting an illiquid over-the-counter version of that stock that’s trading at a massive premium to book values. And so, I am not making UURAF an official recommendation.

Nevertheless, investors with access to Canadian markets may want to consider a small investment in this high-potential firm. America’s government has already invested $400 million into MP Materials, a miner with limited processing capacity. And so, it’s not difficult to see the federal government also putting more cash into Ucore, raising a high price tag even further.

The Risks of a Government Shutdown
Lithium Americas and Ucore are both high-risk plays that depend on government support. They need regulatory approvals to move ahead.

It’s the type of risk that not every investor is comfortable with. And if the government shuts down on September 30, that could put a freeze on new federal contracts, sending shares of these risky firms into a spiral.

But not every firm receiving federal dollars is so risky.

In a recent free presentation, Louis Navellier highlights five firms already posting record profits — companies with the strength to thrive with or without government aid. In fact, a federal shutdown separates the strong from the weak, creating opportunities for investors who position themselves correctly.

Click here to watch Louis cover all the details and reveal the free stock recommendation he believes could surge come September 30.

Until next week,

Thomas Yeung, CFA

Market Analyst, InvestorPlace

Thomas Yeung is a market analyst and portfolio manager of the Omnia Portfolio, the highest-tier subscription at InvestorPlace. He is the former editor of Tom Yeung’s Profit & Protection, a free e-letter about investing to profit in good times and protecting gains during the bad.

2025-09-28 16:05 3mo ago

2025-09-28 12:00 3mo ago

Amazon: The Market Isn't Giving Enough Respect To This Behemoth

stocknewsapi

AMZN

Analyst’s Disclosure:I/we have a beneficial long position in the shares of AMZN, NVDA, META, MSFT, GOOGL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

2025-09-28 16:05 3mo ago

2025-09-28 12:00 3mo ago

UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

stocknewsapi

UNCY

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Unicycive securities between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/UNCY.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1)Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (2) the OLC NDA's regulatory prospects were likewise overstated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/UNCY. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Unicycive you have until October 14, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

2025-09-28 16:05 3mo ago

2025-09-28 12:00 3mo ago

SVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

stocknewsapi

SVRA

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Savara Inc. (“Savara” or “the Company”) (NASDAQ: SVRA) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Savara securities between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/SVRA.

Case Details

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI BLA lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (3) the foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (4) the delay in MOLBREEVI's regulatory approval increased the likelihood that the Company would need to raise additional capital; and (5) as a result, Defendants' public statements were materially false and misleading at all relevant times.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/SVRA. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Savara you have until November 7, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

2025-09-28 16:05 3mo ago

2025-09-28 12:00 3mo ago

NUTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Nutex Health Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

stocknewsapi

NUTX

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Nutex Health Inc. (“Nutex” or “the Company”) (NASDAQ: NUTX) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Nutex securities between August 8, 2024 and August 14, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/NUTX.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) HaloMD was generating lucrative arbitration outcomes for Nutex by engaging in a coordinated scheme to defraud insurance companies; (2) revenues derived from Nutex’s engagement with HaloMD in the IDR process were unsustainable to the extent they resulted from fraudulent conduct; (3) the Company overstated both the extent to which it had remediated, and its ability to remediate, material weaknesses in its internal controls over financial reporting; (4) as a result, Nutex was unable to account for the treatment of certain stock-based compensation obligations effectively; (5) Nutex improperly classified these stock-based compensation obligations as equity rather than liabilities;
(6) the foregoing increased the risk that Nutex would be unable to timely file certain financial reports with the United States Securities and Exchange Commission (“SEC”); (7) accordingly, Nutex’s business and financial prospects were overstated; and (8) as a result, Defendants’ public statements about the Company’s business, operations, and prospects were materially false and misleading at all relevant times.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/NUTX. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Nutex you have until October 21, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

2025-09-28 16:05 3mo ago

2025-09-28 12:00 3mo ago

CHTR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Charter Communications, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

stocknewsapi

CHTR

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Charter Communications, Inc. (“Charter” or “the Company”) (NASDAQ: CHTR) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Charter securities between July 26, 2024 and July 24, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/CHTR.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Charter was not capable of managing the end of the Affordable Connectivity Program (“ACP”); (2) the ACP’s termination resulted in a sustained decline in internet customers and revenue; (3) the Company had no reasonable basis to assert that it was successfully executing its operations plan or effectively managing the causes of customer declines; and (4) as a result, Defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading at all relevant times.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/CHTR. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Charter you have until October 13, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

2025-09-28 16:05 3mo ago

2025-09-28 12:00 3mo ago

AI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that C3.ai, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

stocknewsapi

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against C3.ai, Inc. (“C3.ai” or “the Company”) (NYSE: AI) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired C3.ai securities between February 26, 2025 and August 8, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/AI.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) the health of C3.ai’s Chief Executive Officer was materially impairing the Company’s ability to close deals; (2) management was unable or otherwise ineffectual in mitigating the impact of the CEO’s health on business operations; and (3) as a result, C3.ai’s ability to execute on its profit and growth potential was significantly compromised.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/AI. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in C3.ai you have until October 21, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

2025-09-28 15:05 3mo ago

2025-09-28 10:02 3mo ago

SL Green: More Stable, But Hard To Read Into Its Performance

stocknewsapi

SLG

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

2025-09-28 15:05 3mo ago

2025-09-28 10:10 3mo ago

Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs

stocknewsapi

BBY BMY CAG EQR KEY KIM KMI LYB MAA MO O OKE PFE PM RF SPG UDR VZ

SummarySeven of the top fifteen Barron's Better Bets (BBB) dividend 'dogs' - including CAG, PFE, VZ, BMY, UDR, KIM, and KEY - are attractively priced for income investors.Analyst forecasts project 17.61% to 34.78% net gains for top-ten BBB dogs by September 2026, with an average estimated gain of 23.96% and lower-than-market volatility.Five of the lowest-priced, highest-yield BBB stocks - CAG, PFE, VZ, BMY, and LYB - are expected to outperform higher-priced peers, offering a 16.89% advantage in projected returns.Investors should focus on BBB stocks where annual dividends from $1,000 invested exceed the share price while monitoring for market pullbacks to achieve fair value.In an interview with Barron’s, Steven Wieting, strategist at Citi Wealth, noted that a growing dividend is a tangible benefit for shareholders and a hallmark of companies with strong balance sheets. "Nobody can fake a dividend," he said.Looking for a portfolio of ideas like this one? Members of The Dividend Dog Catcher get exclusive access to our subscriber-only portfolios. Learn More »victorass88/iStock via Getty Images

Foreword While half of this collection of Barron's Better Bets [BBB] is too pricey, or reveals somewhat skinny dividends, seven of the fifteen highest yield Dogs with the "Safest"dividends of the BBB are ready to buy. September finds Conagra (

Analyst’s Disclosure:I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

2025-09-28 15:05 3mo ago

2025-09-28 10:13 3mo ago

Vonovia: Recent Underperformance Presents A Buying Opportunity

stocknewsapi

VNNVF VONOY

Analyst’s Disclosure:I/we have a beneficial long position in the shares of VONOY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

2025-09-28 15:05 3mo ago

2025-09-28 10:15 3mo ago

Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring?

stocknewsapi

LLY

The pharmaceutical company had a clinical setback earlier this year, but that's now in the rearview mirror.

Over the past five years, Eli Lilly (LLY 1.43%) has outperformed the broader market, largely thanks to its progress in the GLP-1 arena. Its major breakthroughs in the field are already leading to incredible commercial success.

But Lilly isn't done just yet. Recent clinical developments may set the stage for further stock-market gains, and potentially allow the drugmaker to maintain that momentum through the end of the decade. Let's find out what Eli Lilly has been up to, and what that means for investors.

The next generation of GLP-1 medicines
Eli Lilly's tirzepatide, marketed under the brands Mounjaro for diabetes and Zepbound for weight management, is highly effective -- and generating billions of dollars in sales per quarter already. However, the medicine is administered subcutaneously once a week. This route has several drawbacks compared to oral pills.

First, the latter are often cheaper to manufacture. With an oral GLP-1 medicine, drugmakers might be able to pass cost savings onto consumers, making them more accessible than their subcutaneous counterparts.

Image source: Getty Images.

Second, oral pills are easier on patients who abhor needles and injections. That's why Lilly and other companies in the field have been racing to develop novel oral GLP-1 therapies. There is already one such treatment on the market: Novo Nordisk's Rybelsus, which was first approved in the U.S. in 2019 and is indicated for the treatment of type 2 diabetes.

But Eli Lilly is on the verge of launching its own oral option. The company's orforglipron performed well in a series of phase 3 studies in diabetes and obesity. What's more, Lilly recently released results from a 52-week study in diabetes patients that pitted orforglipron and Rybelsus head-to-head. During the trial, the highest dose of orforglipron resulted in an average blood-sugar reduction of 1.9%, compared to 1.5% for Rybelsus. Additionally, orforglipron induced an average weight loss of 8.2%, versus 5.3% for Rybelsus.

Once again, Lilly is showing its dominance in this area, even against the company with a first-mover advantage. And if orforglipron is approved by year-end, Eli Lilly's shares could soar. Although the pharmaceutical giant has yet to complete regulatory submissions for orforglipron, some Wall Street analysts believe that the medicine is an excellent candidate for a new program launched by the U.S. Food and Drug Administration, which reduces the 10-month review time for drug applications to a mere one or two months.

Is Lilly overvalued?
No one would question that Eli Lilly is performing extremely well. In the past couple of years, it has arguably produced more positive clinical data in the rapidly growing field of weight management than the rest of the industry combined. And the drugmaker is reaping the rewards of a job well done; its financial results speak for themselves. Second-quarter revenue jumped by 38% year over year to $15.6 billion, while non-GAAP (adjusted) net earnings per share grew 61% to $6.31. Lilly even increased its guidance for the full year 2025.

However, the stock was recently trading at 24.7 times forward earnings estimates, while the average for the healthcare industry is 16.5.

That said, Eli Lilly is worth a hefty premium. Its revenue and earnings are already growing faster than those of its peers. And there are good reasons to believe the pharmaceutical leader will keep that up through the next few years (at the very least), as it continues to benefit from its groundbreaking work in the GLP-1 market. According to some analysts, orforglipron could generate as much as $12.7 billion in revenue by 2030.

Will this medicine cannibalize sales from Lilly's other GLP-1 products? Not at all. Tirzepatide is still growing strongly and could generate nearly $62 billion in revenue by 2030, a figure unheard-of in the industry. A few years ago, some analysts predicted that tirzepatide would peak at $25 billion, which would have been pretty impressive. It's already set to eclipse that number this year, just three years after it first hit the market. Lilly's success in the GLP-1 market has been remarkable and should continue driving solid top-line growth.

Furthermore, several other products will contribute. Lilly's Alzheimer's disease medicine Kisunla has grabbed barely any headlines, but it could also achieve blockbuster status, as could Ebglyss, a new treatment for eczema.

Eli Lilly's outstanding results and prospects justify its valuation, leaving plenty of upside for the company. The stock might not soar based on the recent clinical trial data for orforglipron showing its superiority to Rybelsus unless it leads to regulatory approval by year-end. But Lilly still looks likely to deliver market-beating returns over the next five years.

2025-09-28 15:05 3mo ago

2025-09-28 10:15 3mo ago

This stock is showing striking similar movements to Palantir; Time to buy?

stocknewsapi

SNOW

Palantir Technologies (NASDAQ: PLTR) built its reputation on years of base-building before staging an explosive rally, fueled by growing demand for its government and enterprise AI platforms.

That consolidation phase set the stage for one of the most dramatic moves in recent technology history, with the stock hitting multiple highs in recent months.

As of press time, PLTR shares were trading at $177.57, up 136% year-to-date.

Now, data from charting platform TrendSpider suggests that Snowflake (NYSE: SNOW) may be tracing a similar path.

While its share price has traded sideways since its IPO, revenue has continued to grow steadily quarter after quarter, mirroring Palantir’s pre-breakout pattern.

PLTR and SNOW price chart. Source: TrendSpider
With data emerging as the backbone of AI adoption, the parallels raise the question: could Snowflake be the next Palantir?

PLTR and SNOW stock fundamentals
Palantir’s momentum has been driven by a string of high-profile contracts that expand its dominance in AI-enabled defense and government work.

The company recently secured a $10 billion U.S. Army contract, signed a major partnership with Boeing’s defense unit, and saw NATO adopt its Maven Smart System, all underscoring its role as a critical AI provider in security and defense.

Snowflake, meanwhile, is broadening its platform beyond data warehousing into full AI infrastructure. The company is acquiring Crunchy Data to strengthen its PostgreSQL and AI app development capabilities, positioning it to compete more directly with Databricks.

It has also partnered with Salesforce, dbt Labs, and others on the Open Semantic Interchange initiative, aimed at making enterprise data more interoperable for AI applications.

Leadership changes are also underway. In this case, longtime CFO Mike Scarpelli recently stepped down after overseeing a $3 billion share buyback, a move seen as a vote of confidence in Snowflake’s long-term value.

At the same time, institutional investors have been quietly increasing their stakes, reflecting renewed optimism in the company’s growth trajectory.

Overall, Snowflake’s chart mirrors Palantir’s pre-breakout phase, but while PLTR is already benefiting from major defense contracts, Snowflake is still building its foundation to become an AI-first enterprise platform.

Featured image via Shutterstock

2025-09-28 15:05 3mo ago

2025-09-28 10:17 3mo ago

Mid-America Apartment: Near 52-Week Low Is A Buying Opportunity

stocknewsapi

MAA

SummaryMid-America Apartment Communities is attractively valued near its 52-week low, offering a 4.4% dividend yield and strong fundamentals.MAA benefits from favorable Sunbelt migration trends, stable occupancy, and robust rent collections.MAA's disciplined development, high-return renovations, and A- rated balance sheet support long-term value creation and income growth.I rate MAA as a solid 'Buy,' expecting potential total returns of 10-13% annually as supply normalizes and fundamentals remain resilient.Looking for a portfolio of ideas like this one? Members of iREIT®+HOYA Capital get exclusive access to our subscriber-only portfolios. Learn More » Daniel Grizelj/DigitalVision via Getty Images

Nearly every industry on the market today bears cyclicality, and that’s what makes it possible for patient value investors to capture outsized gains over the long run. This holds especially true for dividend stocks, whose yields go

Analyst’s Disclosure:I/we have a beneficial long position in the shares of MAA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I am not an investment advisor. This article is for informational purposes and does not constitute as financial advice. Readers are encouraged and expected to perform due diligence and draw their own conclusions prior to making any investment decisions.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

2025-09-28 15:05 3mo ago

2025-09-28 10:22 3mo ago

Meta Debuts Next-Gen AI Glasses—A Turning Point for Reality Labs?

stocknewsapi

META

Meta Platforms Today

$743.75 -5.16 (-0.69%)

As of 09/26/2025 04:00 PM Eastern

52-Week Range$479.80▼

$796.25Dividend Yield0.28%

P/E Ratio26.93

Price Target$826.05

Meta Platforms NASDAQ: META recently held one of its biggest events each year: Meta Connect. At this event, the company takes the opportunity to unveil its latest innovations when it comes to consumer devices. This year, Meta released the next generation of its artificial intelligence (AI) glasses: the Meta Ray-Ban Display.

With this device, Mark Zuckerberg may have moved closer to his goal of AI glasses eventually replacing smartphones. However, for investors, what could the Meta Ray-Ban Display mean for the tech stock in the short and long term? Could it be a breakthrough for Meta’s Reality Labs segment? Let’s break down this new device and its potential implications for the stock below.

Get Meta Platforms alerts:

Meta Ray-Ban Display: Huge Advancements, Strong Reviews
Right off the bat, it’s clear that the Meta Ray-Ban Display is a significant upgrade over the company’s past AI glasses. This comes, as the device’s name would suggest; it includes a visual display. Wearers can interact with a two-dimensional display in the right lens.

Users can now operate the device more discreetly with a visible interface, reducing the need to speak and enabling easier public use.

Wearers can use the display to send and receive messages on WhatsApp, Messenger, and Instagram, and access a map that provides turn-by-turn walking directions. They can also now see a preview of the picture or video they want to capture.

Before, capturing images with the Ray-Ban glasses was somewhat of a guessing game. Meta says this image previewing feature was the number one request it received from users of the previous device. The device can also provide subtitles and translate foreign languages when speaking to another person.

Despite these considerable advancements, the most interesting feature of the device is how wearers interact with the display. With the glasses comes a wristband called the Meta Neural Band.

The band reads electric impulses from the user's arm to detect hand gestures corresponding to different controls. Early reviews of the device have been generally very positive, with Engadget’s Karissa Bell saying it "feels like the beginning of the kind of smart glasses a lot of people have been waiting for."

Strong Adoption Could Alter Investor Outlook on Reality Labs
With this new tech, Meta seems to have taken a big step forward in its mission to one day replace smartphones with AI glasses.

Still, it can’t do nearly as much as a smartphone, and the number of applications users can access is very small. Thus, the Meta Ray-Ban Display doesn’t make the firm any type of real threat to Apple NASDAQ: AAPL at this point. However, the device can add upside to Meta's shares.

Compared to past Meta glasses, the visual display is much more aligned with what smartphones offer. Thus, they provide a tangible and early demonstration of a product that, with further advancements, could compete significantly with smartphones.

Meta Platforms Stock Forecast Today12-Month Stock Price Forecast:
$826.05
11.06% Upside

Moderate Buy
Based on 47 Analyst Ratings

Current Price$743.75High Forecast$980.00Average Forecast$826.05Low Forecast$600.00Meta Platforms Stock Forecast Details

If sales are strong, the prospect of widespread adoption of AI glasses in the future becomes more realistic, as consumers show they are open to this potential future. Seeing this positively shift sentiment on Reality Labs wouldn't be overly surprising.

So far, many have viewed the segment as a nuisance on Meta’s income statement, tolerated due to its impressive advertising business.

The success of the Meta Ray-Ban Display could change this view, positioning Reality Labs as a business with a more verifiable chance of long-term success.

This could create positive near-to-mid-term price action in Meta shares when data on the device’s sales comes out. However, if adoption is weak, an opposite reaction could also occur. Still, Reality Labs has been losing over $3 billion a quarter for at least two years.

Nonetheless, Meta shares have soared over that time, showing that markets aren’t holding this against the company much.

AI Glasses Continue to Add Long-Term Upside Potential
Longer term, the rapid advancement of Meta’s AI glasses continues to support the notion that Meta could one day become a worldwide leader in AI hardware. Its current place as a leader in social media and AI advertising makes it a difficult company to bet against.

Whether its latest device will be a breakthrough for Reality Labs remains in question, but the bullish outlook for the stock continues until something significant changes.

Should You Invest $1,000 in Meta Platforms Right Now?Before you consider Meta Platforms, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Meta Platforms wasn't on the list.

While Meta Platforms currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

2025-09-28 15:05 3mo ago

2025-09-28 10:30 3mo ago

5 Dividend Powerhouses Every Investor Should Own

stocknewsapi

JPM LMT NVDA PG XOM

From defense contracts to AI chips, these dividend giants dominate their industries while rewarding shareholders with growing cash distributions.

Forget chasing the next hype-fueled stock. Real wealth comes from companies that dominate essential industries and return cash to shareholders year after year. These dividend powerhouses span consumer goods, defense, energy, and finance, with records of resilience through recessions, wars, and market crashes.

The formula is simple: durable businesses, consistent cash flows, and dividends that continue to rise. The beauty is boring predictability -- exactly what long-term investors should want.

Image source: Getty Images.

The defense dividend fortress
Lockheed Martin (LMT 0.66%) yields 2.7% with support from one of the most reliable customers in the world: the U.S. government. Its flagship F-35 fighter program is slated to run into the 2070s, providing decades of predictable revenue that have fueled 6.6% annual dividend growth over the past five years.

While its 73% payout ratio looks elevated, it is supported by an $886 billion U.S. defense budget and record global military spending. With geopolitical tensions from Ukraine to Taiwan driving defense outlays higher, Lockheed offers one of the most secure dividends investors can find.

The consumer staples cash machine
Procter & Gamble (PG 0.21%) yields about 2.8% and owns some of the world's most essential consumer brands -- Tide, Pampers, Gillette, Crest -- generating durable demand across economic cycles. The company has paid a dividend every year since 1890 (134 consecutive years) and has raised it for nearly seven decades.

With 6% average dividend growth over five years and a forward payout ratio in the low 60s, P&G is a textbook example of steady income compounded over time. Its strong brand power and ability to raise prices in inflationary periods provide a buffer, letting P&G maintain margins when input costs rise.

The energy income giant
ExxonMobil (XOM 1.35%) offers a 3.4% yield that looks attractive in an era when many investors discount traditional energy stocks due to transition fears. Dividend growth has averaged just 2.6% annually over the past five years, but a 56% payout ratio leaves room for steady increases as oil demand remains resilient.

The Pioneer acquisition cemented Exxon's dominance in the Permian Basin, while massive offshore Guyana discoveries provide decades of low-cost production. Add in the stability of its chemicals and refining operations, and with industrywide capital discipline replacing past drilling excesses, Exxon's dividend looks increasingly sustainable.

The AI growth paradox
Nvidia (NVDA 0.27%) sports an almost invisible 0.02% yield, but that misses the point entirely. The real story: 20% annual dividend growth over five years from a minuscule 1.1% payout ratio. This isn't an income play today -- it's tomorrow's dividend champion being born.

With artificial intelligence (AI) demand creating unprecedented pricing power and a gross margin above 70%, Nvidia could multiply its dividend 50-fold and barely notice. Buying for current yield would be foolish, but ignoring the dividend growth potential would be equally shortsighted.

The banking profit printer
JPMorgan Chase (JPM 0.83%) yields 1.9% with reliability, growing its dividend 8% annually over five years while maintaining a conservative 27.2% payout ratio. CEO Jamie Dimon built a fortress balance sheet that survived the regional banking crisis without breaking a sweat.

The bank's diversified revenue streams -- from investment banking to wealth management to credit cards -- provide stability through any rate cycle. With the conservative payout ratio leaving massive room for increases and the business model proven resilient through multiple economic shocks, JPMorgan's dividend growth looks set to continue regardless of Federal Reserve policy.

The dividend diversification playbook
These five stocks create a perfectly balanced dividend portfolio. ExxonMobil and P&G provide immediate income at 3.4% and 2.8% yields. Lockheed and JPMorgan offer steady growth with defensive characteristics. Nvidia represents the moonshot -- negligible current income but potentially explosive future payouts.

Together they span defense, consumer goods, energy, technology, and financials -- sectors that rarely crash simultaneously. Average the yields and you get 2.2%, but focus on the payout ratios, averaging just 46%, and you see the real opportunity: massive dividend growth ahead.

JPMorgan Chase is an advertising partner of Motley Fool Money. George Budwell has positions in JPMorgan Chase, Lockheed Martin, and Nvidia. The Motley Fool has positions in and recommends JPMorgan Chase and Nvidia. The Motley Fool recommends Lockheed Martin. The Motley Fool has a disclosure policy.

2025-09-28 15:05 3mo ago

2025-09-28 10:40 3mo ago

Euphoric Valuation Takes The Shine Off Rheinmetall AG's Solid Fundamentals

stocknewsapi

RNMBF RNMBY

2025-09-28 15:05 3mo ago

2025-09-28 10:40 3mo ago

How To Survive A 30% Market Crash In Retirement

stocknewsapi

BAM DB ENB NEE PM SCHD SPY VOO

SummarySequence of return risk can devastate retirement portfolios, especially when early negative returns coincide with withdrawals, undermining the traditional 4% rule.Dividend investing offers a powerful solution by providing steady cash flows that are largely independent of market volatility, neutralizing sequence risk.Building a portfolio of high-quality, dividend-growing stocks can deliver superior returns and reduce stress.Following a disciplined approach of buying undervalued dividend stocks and selling when overvalued ensures income growth, portfolio resilience, and protection against inflation.Looking for a helping hand in the market? Members of The Dividend Freedom Tribe get exclusive ideas and guidance to navigate any climate. Learn More » Arsgera/iStock via Getty Images

Written by Sam Kovacs

Introduction Retiring just before a market crash will wreak havoc in a retirement portfolio.

This danger is well documented and researched. It is referred to as "sequence of return" risk: it's the risk that the

Analyst’s Disclosure:I/we have a beneficial long position in the shares of PM, ENB, NEE, BAM, DB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

2025-09-28 15:05 3mo ago

2025-09-28 10:46 3mo ago

These 3 Dividend ETFs Pay Monthly, But Also Have Big Upside Potential

stocknewsapi

DIA PFF PGX

Creating passive income streams can take many forms. Investors can choose from a plethora of stocks, bonds, alternative assets (such as real estate) and other less-traditional options (including crypto, etc.

2025-09-28 15:05 3mo ago

2025-09-28 10:54 3mo ago

CHTR ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Class Action Lawsuit Against Charter Communications, Inc. (CHTR)

stocknewsapi

CHTR

, /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Charter Communications, Inc. ("Charter") (NASDAQ: CHTR) on behalf of those who purchased or otherwise acquired Charter securities, including purchasers of call options, or sellers of put options, between July 26, 2024, and July 24, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is October 14, 2025.

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered Charter losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/charter-communications-inc?utm_source=PR_Newswire&mktm=PR

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at[email protected].

DEFENDANTS' ALLEGED MISCONDUCT:
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the impact of the cancelation of the Affordable Connectivity Program ("ACP") was a material event Charter was unable to manage or promptly move beyond; (2) the ACP end was actually having a sustaining impact on Internet customer declines and revenue; (3) Charter was not executing broader operations in a way that would compensate for, or overcome the impact, of the ACP ending; (4) the Internet customer declines and broader failure of Charter's execution strategy created much greater risks on business plans and earnings growth than reported; (5) accordingly, Charter had no reasonable basis to state the company was successfully executing operations, managing causes of Internet customer declines, or provide overly optimistic statements about the long term trajectory of Charter and its EBITDA growth; and (6) as a result, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/MvQfxMhmwQY

THE LEAD PLAINTIFF PROCESS:
Charter investors may, no later than October 14, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages Charter investors who have suffered significant losses to contact the firm directly to acquire more information.

CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/charter-communications-inc?utm_source=PR_Newswire&mktm=PR

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

SOURCE Kessler Topaz Meltzer & Check, LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 15:05 3mo ago

2025-09-28 10:55 3mo ago

Why Teradyne Is a Core Play in the AI Hardware Boom

stocknewsapi

TER

Teradyne Today

$135.31 +2.44 (+1.84%)

As of 09/26/2025 04:00 PM Eastern

52-Week Range$65.77▼

$144.16Dividend Yield0.35%

P/E Ratio46.82

Price Target$118.63

A recent jump in Teradyne's NASDAQ: TER stock, which saw it climb over 12% in a single trading session, has caught the market's attention. Such a move is significant for a company with a market capitalization of $21 billion.

It begs the question: Why is a company specializing in semiconductor test equipment suddenly demonstrating such strong momentum?

A closer look reveals this is not a momentary spike but a market awakening to a deeper reality: Teradyne has become an indispensable and foundational player in the artificial intelligence (AI) revolution.

While much of the focus in the AI space is on high-profile chip designers, the success of the entire industry rests on the ability to produce incredibly complex hardware that works flawlessly. This is where Teradyne provides its value.

The company operates as a classic picks and shovels play, supplying the essential tools needed to ensure the gold rush in AI hardware pays off.

The recent stock performance suggests that investors are beginning to fully understand and appreciate the value of the one selling the tools.

Forging the Tools for the AI Era
The primary force behind Teradyne's renewed momentum is AI hardware's explosive growth and complexity. As AI models become more sophisticated, the chips that power them are evolving into technological marvels of unprecedented density and complexity.

This creates a critical challenge for manufacturers: ensuring quality and yield. The cost of a single defect in a multi-thousand-dollar AI accelerator is enormous, making rigorous testing a crucial quality control step and an economic necessity.

This is where demand for Teradyne's advanced equipment is igniting. On the company's second quarter 2025 earnings call, CEO Greg Smith confirmed this shift, stating that he expects AI compute to be the dominant driver of the core Semiconductor Test business for the rest of the year.

The company is backing this strategy with targeted innovation. Its recently launched Magnum 7H memory tester is a prime example.

This system is purpose-built to handle the unique challenges of testing High Bandwidth Memory (HBM), the ultra-fast memory stacked directly onto high-performance AI GPUs.

With the Magnum 7H already shipping to major HBM manufacturers, Teradyne has a direct line to profit from every new AI server that gets built.

This is further supported by strategic moves, such as the acquisition of Quantifi Photonics, which bolsters its position in testing another critical AI component: silicon photonics.

Where Teradyne’s Strategy Meets the Bottom Line
This strategic positioning in the AI supply chain is already translating into solid financial performance. While second-quarter revenue was down year-over-year, a reflection of residual weakness in consumer and automotive markets, the company's forward guidance signals a powerful, AI-driven rebound is underway.

Key financial metrics highlight this turning point:

Beating Expectations: For Q2 2025, Teradyne reported revenue of $651.8 million and non-GAAP earnings per share (EPS) of $0.57, comfortably surpassing analyst estimates.
Strong Forward Guidance: For Q3 2025, management projects revenue to land between $710 million and $770 million. At the midpoint, this represents a powerful 14% sequential growth rate, giving concrete financial weight to management's optimism.
Profitability and Valuation: The company's non-GAAP operating profit was 15.1% in the second quarter and is projected to expand to 19.5% at the midpoint of Q3 guidance. With a trailing price-to-earnings ratio (P/E) of approximately 46, the stock is valued for its growth potential, which upcoming quarters are forecast to deliver.
Shareholder Returns: This financial strength supports healthy shareholder returns, including a consistent quarterly dividend of $0.12 per share and an active share repurchase program, which removed $119 million of stock from the market in the second quarter alone.

Wall Street's Re-rating Begins
Teradyne Stock Forecast Today12-Month Stock Price Forecast:
$118.63
-12.33% Downside

Moderate Buy
Based on 18 Analyst Ratings

Current Price$135.31High Forecast$200.00Average Forecast$118.63Low Forecast$85.00Teradyne Stock Forecast Details

Following the stock's recent ascent, investors are asking what comes next. A review of Wall Street activity suggests that a reevaluation is in its early stages. According to data from 18 analysts, Teradyne holds a Moderate Buy consensus rating.

While its average price target of $118.63 sits below the current trading price, older targets weigh down this figure.

The most recent analyst revisions, however, show a decidedly bullish trend. For example, Susquehanna recently boosted its price target to $200, citing AI-driven opportunities. This type of revision suggests that some analysts are actively re-rating the stock's potential as the AI growth story becomes clearer.

The breakdown of 11 Buy ratings, 5 Hold ratings, and 2 Sell ratings suggests that positive sentiment is strong, despite the consensus target still falling short of the stock's recent price action.

A Core Holding for the AI Infrastructure Buildout
Teradyne's recent surge is more than just a momentary market reaction; it reflects a fundamental shift in its business. The company's deep-seated expertise in testing complex electronics has placed it at the center of a generation's most significant technological transition.

As the buildout of AI infrastructure continues, the demand for more complex and powerful chips will only grow. With it, the need for the critical testing technology that Teradyne provides will become even more pronounced.

For investors seeking a foundational way to participate in the AI megatrend, Teradyne is moving beyond its cyclical semiconductor identity and emerging as a secular growth story, making it a compelling consideration for any technology-focused portfolio.

Should You Invest $1,000 in Teradyne Right Now?Before you consider Teradyne, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teradyne wasn't on the list.

While Teradyne currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

2025-09-28 15:05 3mo ago

2025-09-28 11:00 3mo ago

DOW Investors: October 28, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

stocknewsapi

DOW

, /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Dow Inc. ("Dow") (NYSE: DOW) on behalf of those who purchased or otherwise acquired Dow securities between January 30, 2025, and July 23, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is October 28, 2025.

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered Dow losses, you may CLICK HERE or copy and paste the following link into your browser:https://www.ktmc.com/new-cases/dow-inc?utm_source=PR_Newswire&mktm=PR

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].

DEFENDANTS' ALLEGED MISCONDUCT:
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Dow's ability to mitigate macroeconomic and tariff-related headwinds, as well as to maintain the financial flexibility needed to support its lucrative dividend, was overstated; (2) the true scope and severity of the foregoing headwinds' negative impacts on Dow's business and financial condition was understated, particularly with respect to competitive and pricing pressures, softening global sales, and demand for Dow's products, as well as an oversupply of products in Dow's global markets; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/41CEzLbyvm0

THE LEAD PLAINTIFF PROCESS:
Dow investors may, no later than October 28, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages Dow investors who have suffered significant losses to contact the firm directly to acquire more information.

CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/dow-inc?utm_source=PR_Newswire&mktm=PR

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

SOURCE Kessler Topaz Meltzer & Check, LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Snap, Inc. of Class Action Lawsuit and Upcoming Deadlines - SNAP

stocknewsapi

SNAP

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Snap, Inc. ("Snap" or the "Company") (NYSE: SNAP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Snap and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 20, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Snap securities during the Class Period. A copy of the Complaint can be obtained a t www.pomerantzlaw.com .

[Click here for information about joining the class action]

On August 5, 2025, Snap announced its financial results for the second quarter of fiscal year 2025, disclosing a deceleration in advertising revenue growth. The Company attributed the slowdown to "an issue related to our ad platform, the timing of Ramadan, and the effects of the de minimis changes."

On this news, Snap's stock price fell $1.61 per share, or 17.15%, to close at $7.78 per share on August 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amer Sports, Inc. - AS

stocknewsapi

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amer Sports, Inc. ("Amer" or the "Company") (NYSE: AS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Amer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On September 19, 2025, Amer's flagship brand Arc'teryx conducted a promotional fireworks display in Tibet, prompting a backlash from environmentalists and triggering an investigation by Chinese authorities.

Amer's stock price subsequently fell $2.18 per share, or 5.82%, to close at $35.27 per share on September 22, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

stocknewsapi

SLNO

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

      The investigation concerns whether Soleno and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

      On August 15, 2025, Scorpion Capital ("Scorpion") published a report that described Soleno's only product, Vykat XR, as overpriced and potentially unsafe for children.

      Following publication of the Scorpion report, Soleno's stock price fell $5.73 per share, or 7.41%, to close at $71.63 per share on August 15, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skillz Inc.- SKLZ

stocknewsapi

SKLZ

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skillz Inc. ("Skillz" or the "Company") (NYSE: SKLZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Skillz and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On September 2, 2025, Skillz disclosed in a filing with the U.S. Securities and Exchange Commission that Tether Studios and its affiliate Tether Games (together, "Tether") plan to terminate all agreements with Skillz, effective September 1, 2025. Under the agreements, Skillz has licensed its software to Tether for use in monetizing Tether's games. In return, both companies share the revenue from user entry fees. After receiving the notice, Skillz filed a lawsuit on September 1, 2025, seeking to block Tether's termination of their agreements. Skillz is also disputing Tether's reasons for ending the deal.

On this news, Skillz's stock price fell $1.50 per share, or 17.22%, to close at $7.21 per share on September 3, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innovative Solutions and Support, Inc. - ISSC

stocknewsapi

ISSC

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Innovative Solutions and Support, Inc. ("IS&S" or the "Company") (NASDAQ: ISSC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether IS&S and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On August 14, 2025, IS&S issued a press release announcing its financial results for its fiscal third quarter of 2025. Therein, the Company's Chief Executive Officer Shahram Askarpour advised, among other things, that a "pull-forward of F-16 production into the current quarter . . . will impact revenue over the next two quarters[.]"

On this news, IS&S's stock price fell $6.22 per share, or 31.53%, to close at $13.51 per share on August 14, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CPI Card Group Inc. - PMTS

stocknewsapi

PMTS

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CPI Card Group Inc. ("CPI" or the "Company") (NASDAQ: PMTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether CPI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On August 8, 2025, CPI announced second quarter 2025 financial results that missed top-line and bottom-line estimates. Among other items, CPI reported a GAAP earnings-per-share figure of $0.04 per share, missing estimates by $0.46, and revenue of $129.75M, missing estimates by $3.21M. In addition, the Company updated its outlook for 2025, stating that it expects net sales in low double-digit to mid-teens growth, compared to the prior outlook of mid-to-high single-digit growth. CPI stated that the change from the prior outlook reflects the addition of Arroweye Solutions, Inc.—an on-demand payment card solutions provider acquired by CPI in May 2025—partially offset by the negative impact of the accounting change for revenue recognition timing of work-in-process orders.

On this news, CPI's stock price fell $5.37 per share, or 28.83%, to close at $13.25 per share on August 8, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

Pomerantz Law Firm Announces the Filing of a Class Action Against CTO Realty Growth, Inc. and Certain Officers - CTO

stocknewsapi

CTO

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against CTO Realty Growth, Inc. ("CTO" or the "Company") (NYSE: CTO) and certain officers. The class action, filed in the United States District Court for the Middle District of Florida, and docketed under 25-cv-01516, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired CTO securities between February 18, 2021 and June 24, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired CTO securities during the Class Period, you have until October 7, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

CTO is a publicly traded real estate investment trust ("REIT") that owns and operates a portfolio of purported high-quality, retail-based properties located primarily in higher growth markets in the United States ("U.S."). The Company converted into a REIT in February 2021 and, as of December 31, 2024, owned 23 income properties in seven states, including Ashford Lane, a retail and dining center in Atlanta, Georgia.

Under guidelines established by the U.S. Securities and Exchange Commission ("SEC"), REITs must pay out at least 90% of their taxable profits to shareholders annually as dividends. In return, REIT companies are exempt from most corporate income tax. CTO has touted that its operation as a REIT "provides the tax-efficient organizational structure for [its] stockholders" that "will allow [it] to provide them with an attractive and sustainable dividend."

To measure its performance, CTO uses the financial metric Adjusted Funds from Operations ("AFFO"). The AFFO of a REIT, though subject to varying methods of computation, is generally equal to the REIT's funds from operations with adjustments made for recurring capital expenditures (also referred to as "capex") used to maintain the quality of the REIT's underlying assets. Professional analysts tend to prefer AFFO because it takes into consideration additional costs incurred by the REIT as well as additional income sources, such as rent increases. Thus, analysts believe that AFFO provides for a more accurate base number when estimating present values and a better predictor of the REIT's future ability to pay dividends.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) CTO's dividends were less sustainable than Defendants had led investors to believe; (ii) the Company used deceptive and unsustainable practices to artificially inflate its AFFO and overstate the true profitability of its Ashford Lane property; (iii) accordingly, CTO's business and/or financial prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On June 25, 2025, Wolfpack Research ("Wolfpack") published a report entitled "CTO: The B. Riley of REITs" (the "Wolfpack Report" or the "Report"), which compared CTO unfavorably to B. Riley, a financial services company that recently lost more than 90% of its value amid three years of losses, soured investments, delayed financial reports and revelations that the SEC had been investigating whether the firm gave shareholders an accurate picture of its health. Citing interviews with former employees and whistleblowers, the Wolfpack Report accused CTO of, among other things, "not generat[ing] enough cash to pay its recurring capex and cover its dividends since converting to a REIT in 2021" and instead "rel[ying] on dilution (increasing shares outstanding by 70% since December 2022) to cover a $38 million dividend shortfall from 2021 to 2024," employing a "manipulative definition of [AFFO] where they exclude recurring capex, unlike all of their self-identified shopping center REIT peers," and "us[ing] a sham loan to hide the collapse of a top tenant from shareholders at Ashford Lane." (Emphasis in original). Further, Wolfpack predicted imminent further dilution of the Company, noting that CTO has just $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million per quarter, along with approximately $12 million in additional planned capital expenditures.

On this news, CTO's stock price fell $0.98 per share, or 5.42%, to close at $17.10 per share on June 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

Pomerantz Law Firm Announces the Filing of a Class Action Against Tesla, Inc. and Certain Officers - TSLA

stocknewsapi

TSLA

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tesla, Inc. ("Tesla" or the "Company") (NASDAQ: TSLA) and certain officers. The class action, filed in the United States District Court for the Western District of Texas, and docketed under 25-cv-01213, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Tesla securities between April 19, 2023 and June 22, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Tesla securities during the Class Period, you have until October 4, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Tesla designs, develops, manufactures, leases, and sells electric vehicles and autonomous driving vehicles, as well as energy generation and storage systems, in the United States ("U.S."), China, and internationally. The Company offers certain advanced driver assist systems in its vehicles under its Autopilot and Full Self-Driving (Supervised) options which purportedly "intelligently and accurately complete [] driving maneuvers for you [i.e., the driver], including route navigation, steering, lane changes, parking and more under your active supervision."

In April 2022, at an event celebrating the opening of the Company's Gigafactory Texas global headquarters and manufacturing facility, Tesla's Chief Executive Officer Defendant Elon Musk announced that the Company would be building a vehicle dedicated for use as a robotaxi (the "Robotaxi"). Tesla has touted its Robotaxi business as a "ride-hailing network that will eventually operate fully autonomous vehicles" and has stated that "[w]e expect this business will open access to a new customer base even as modes of transportation evolve. We believe our capabilities and advancements in [artificial intelligence], including the deployment of Cortex, our training cluster at Gigafactory Texas, differentiates us from our competitors."

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Tesla overstated the effectiveness of its autonomous driving technology; (ii) there was thus a significant risk that the Company's autonomous driving vehicles, including the Robotaxi, would operate dangerously and/or in violation of traffic laws; (iii) the foregoing increased the likelihood that Tesla would become subject to heightened regulatory scrutiny; (iv) accordingly, Tesla's business and/or financial prospects were overstated; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

On June 22, 2025, Tesla debuted its Robotaxi service with a highly publicized launch event in Austin, Texas. At the event, approximately 10 autonomous driving Robotaxis with a "safety monitor" in the front passenger seat began picking up invite-only passengers in a geofenced 10-mile by five-mile square of Austin.

The next day, Bloomberg published an article entitled "Tesla Robotaxi Videos Show Speeding, Driving Into Wrong Lane," which reported that "Tesla Inc.'s self-driving taxis appeared to violate traffic laws during the company's first day offering paid rides, with one customer capturing footage of a left turn gone wrong and others traveling in cars that exceeded posted speed limits." That same day, in an article entitled "Tesla Robotaxi Incidents Draw Scrutiny From US Safety Agency," Bloomberg reported that the U.S. National Highway Traffic Safety Administration ("NHTSA") had contacted Tesla regarding the foregoing incidents, noting that the NHTSA "is aware of the incidents that were captured in videos posted on social media and is gathering additional information from the company." Further, the Bloomberg article quoted a statement released by the agency that "[f]ollowing an assessment of those reports and other relevant information, NHTSA will take any necessary actions to protect road safety." Then on June 24, 2025, in an article entitled "NHTSA Now Targets Tesla Robotaxi After Autonomous EVs Break Traffic Laws," International Business Times stated, in relevant part, that "the emergence of videos showing concerning behaviour by Tesla's robotaxis may dampen public enthusiasm. The controversy has also triggered fresh criticism and could impact the scheduled rollout later this month."

Following these reports, Tesla's stock price fell $21.13 per share over two trading sessions, or 6.05%, to close at $327.55 per share on June 25, 2025.

After the end of the Class Period, on August 1, 2025, it was reported that a jury in a trial in the U.S. District Court for the Southern District of Florida determined that Tesla should be held partly liable for a fatal 2019 Autopilot crash, and must compensate the family of the deceased and an injured survivor a portion of $329 million in damages.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Coty Inc. - COTY

stocknewsapi

COTY

NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Coty Inc. ("Coty" or the "Company") (NYSE: COTY).

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

stocknewsapi

AXGN

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Axogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On August 25, 2025, Axogen issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025."

On this news, Axogen's stock price fell $1.47 per share, or 9.04%, to close at $14.79 per share on August 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR

stocknewsapi

JSPR

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08010, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Jasper securities during the Class Period, you have until November 18, 2025 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible Urticaria ("CIndU"), and Asthma. The Company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor ("SCF") from binding to and signaling through the CD117 ("c-Kit") receptor on mast and stem cells. According to Jasper, the "SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s] that blocking this pathway may lead to depletion of these cells throughout the body, including in the lungs and in the skin, which could lead to significant clinical benefit for patients with mast-cell driven diseases such as asthma and chronic urticarias" and "[t]o that end, [Jasper is] focusing on advancing a portfolio of clinical programs in mast cell driven diseases." In 2024, to "strengthen [its] balance sheet and support development of briquilimab," Jasper completed an oversubscribed $50 million financing "with a syndicate of leading life science investors," purportedly "extending [its] cash runway through the third quarter of 2025."

In November 2023, the Company commenced a Phase 1b/2a clinical study of subcutaneous briquilimab for the treatment of CSU (the "BEACON Study"). When announcing the first patient dosing in the BEACON Study, Jasper's Chief Executive Officer Defendant Ronald Martell stated, in relevant part, that he was "confident in the ability of our clinical organization to continue to execute at a high level as we advance briquilimab into clinical trials in CIndU and other mast cell-driven diseases." In December 2024, the Company commenced a Phase 1b/2a clinical study evaluating briquilimab in allergic asthma (the "ETESIAN Study"). In addition, Jasper has attempted to develop briquilimab as a one-time conditioning therapy for severe combined immunodeficiency ("SCID") patients undergoing a second stem cell transplant.

Under the Drug Supply Chain Security Act —a law enacted by Congress in 2013 designed to improve and ensure the safety of the U.S pharmaceutical supply chain—all prescription drugs must be labeled with a unique product identifier that includes, among other things, a "lot number." Drug "lots" are batches of a product that are manufactured, processed, packaged, or stored under the same conditions. If a medication is compromised, pharmaceuticals companies can use lot numbers to trace the affected batches and alert healthcare providers.

According to the Company, "[t]he manufacture of pharmaceuticals is subject to extensive [current Good Manufacturing Practices ("cGMP")] regulations, which impose various procedural and documentation requirements and govern all areas of record keeping, production processes and controls, personnel and quality control." Because Jasper does not currently own or operate any manufacturing facility, the Company relies on third-party contract manufacturing organizations to produce its drug candidates in purported "accordance with cGMP regulations for use in [its] clinical studies."

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On July 7, 2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed with drug from the lot in question," that "[t]he Company is investigating the drug product lot in question and expects to have the results of that investigation in the coming weeks," and that Jasper was "taking steps to ensure that drug product from the lot in question is returned to the Company and that sites have drug product from other lots to continue dosing." Further, the press release revealed that the Company "has also determined that the drug product lot in question was used to treat participants enrolled in the ETESIAN [Study]. As a result, and in order to focus resources on advancing briquilimab in CSU, the Company is halting the study and pausing development in asthma." Finally, the press release stated that "the Company is halting development in SCID" and, contrary to its prior representation of having a strong balance sheet and a cash runway extending "through the third quarter of 2025," that Jasper "will be implementing a number of other cost cutting measures including a potential restructuring, to extend runway and reduce expenses."

On this news, Jasper's stock price fell $3.73 per share, or 55.1%, to close at $3.04 per share on July 7, 2025.

Market analysts were quick to comment on the Company's announcement. For example, on July 7, 2025, BMO Capital Markets published a report downgrading Jasper to market perform and lowering its price target from $6.77 per share to $4.00 per share (the "BMO Report"). The BMO Report stated, in relevant part, that "potential Briquilimab drug lot issues, coupled with existing uncertainty around dose-response [], will pressure the [Jasper] story moving forward" given, among other things, Jasper's "financing overhang" and market competition.

After the end of the Class Period, on July 9, 2025, the Company issued a press release entitled "Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway." The press release revealed that Jasper was reducing its workforce by approximately 50%, that "[i]n order to focus resources on the development of briquilimab in chronic urticaria, Jasper is halting its other clinical and preclinical programs," and that Defendant Edwin Tucker was departing his role as the Company's Chief Medical Officer effective August 1, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

Pomerantz Law Firm Announces the Filing of a Class Action Against Fluor Corporation and Certain Officers - FLR

stocknewsapi

FLR

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fluor Corporation ("Fluor" or the "Company") (NYSE: FLR) and certain officers. The class action, filed in the United States District Court for the Northern District of Texas, Dallas Division, and docketed under 25-cv-02496, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fluor securities between February 18, 2025 and July 31, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Fluor securities during the Class Period, you have until November 14, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Fluor provides engineering, procurement, and construction ("EPC"), fabrication and modularization, and project management services worldwide. The Company operates through three segments: Urban Solutions, Energy Solutions, and Mission Solutions.

Throughout 2024 and the first quarter of 2025, Fluor's Urban Solutions segment accounted for the largest portion of the Company's revenue and profit. The Urban Solutions segment offers EPC and project management services to the advanced technologies and manufacturing, life sciences, mining and metals, and infrastructure industries, as well as provides professional staffing services. The Company's infrastructure projects in this segment include work on, inter alia, the Gordie Howe International Bridge ("Gordie Howe"), as well as the Interstate 365 Lyndon B. Johnson ("I-635/LBJ") and Interstate 35E ("I-35") highways in Texas.

In February 2025, Fluor provided financial guidance for the full year ("FY") of 2025, including adjusted EBITDA of $575 million to $675 million and adjusted earnings per share ("EPS") of $2.25 per share to $2.75 per share. Defendants reaffirmed the foregoing financial guidance in May 2025, notwithstanding their acknowledgement of the potential negative impacts of ongoing economic uncertainty on Fluor's business resulting from trade tensions and other market conditions. Contemporaneously, Defendants touted, inter alia, the purported health and stability of Fluor's and its customers' operations and the strength of the Company's risk mitigation strategy, both for itself and its clients.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Fluor's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) costs associated with the Gordie Howe, I-635/LBJ, and I-35 projects were growing because of, inter alia, subcontractor design errors, price increases, and scheduling delays; (ii) the foregoing, as well as customer reduction in capital spending and client hesitation around economic uncertainty, was having, or was likely to have, a significant negative impact on the Company's business and financial results; (iv) accordingly, Fluor's financial guidance for FY 2025 was unreliable and/or unrealistic, the effectiveness of the Company's risk mitigation strategy was overstated, and the impact of economic uncertainty on the Company's business and financial results was understated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On August 1, 2025, Fluor issued a press release reporting its financial results for the second quarter ("Q2") of 2025. Among other results, the press release reported Q2 non-GAAP EPS of $0.43, missing consensus estimates by $0.13, and revenue of $3.98 billion, representing a 5.9% year-over-year decline and missing consensus estimates by $570 million. Defendants blamed these disappointing results on, inter alia, growing costs in multiple infrastructure projects due to subcontractor design errors, price increases, and scheduling delays, as well as reduced capital spending by customers. The same press release also provided a negatively revised financial outlook for FY 2025, guiding to adjusted EBITDA of $475 million to $525 million, down significantly from Defendants' prior guidance of $575 million to $675 million, and adjusted EPS of $1.95 per share to $2.15 per share, down significantly from Defendants' prior guidance of $2.25 per share to $2.75 per share, citing "client hesitation around economic uncertainty and its impact on new awards and project delays and results for the quarter[.]"

The same day, Fluor hosted a conference call with investors and analysts to discuss the Company's Q2 2025 financial results. During that call, the Company's Chief Executive Officer, Defendant James R. Breuer, disclosed that the infrastructure projects that had negatively impacted Fluor's Q2 2025 results were the Gordie Howe, I-635/LBJ, and I-35 projects.

Following the foregoing disclosures, Fluor's stock price fell $15.35 per share, or 27.04%, to close at $41.42 per share on August 1, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lesaka Technologies, Inc. - LSAK

stocknewsapi

LSAK

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lesaka Technologies, Inc. ("Lesaka" or the "Company") (NASDAQ: LSAK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Lesaka and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On September 10, 2025, Lesaka disclosed in a filing with the U.S. Securities and Exchange Commission ("SEC") that the Audit Committee of its Board of Directors had "concluded that the Company's unaudited condensed consolidated financial statements for the quarters ended September 30, 2024, December 31, 2024, and March 31, 2025, respectively, included in the Company's Quarterly Reports on Form 10-Q for the quarters ended September 30, 2024, December 31, 2024, and March 31, 2025, respectively (the "Quarterly Reports"), should be restated, and that such unaudited condensed financial statements should no longer be relied upon, due to the Company's re-evaluation of the classification of certain revenue that has been reported as an agent rather than as principal, and related cost of goods sold."

On this news, Lesaka's stock price fell $0.48 per share, or 10.15%, to close at $4.25 per share on September 11, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediaAlpha, Inc. - MAX

stocknewsapi

MAX

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediaAlpha, Inc. ("MediaAlpha" or the "Company") (NYSE: MAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether MediaAlpha and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On June 24, 2024, Wolfpack Research published a report entitled "MAX: Our Investigation Reveals MAX Is Participating in Consumer Fraud." In pertinent part, Wolfpack announced that it was "short the insurance lead generator, MediaAlpha, Inc. (NYSE: MAX) following our research into the company's [Health Insurance] segment[.]" Wolfpack stated that it believed "[MediaAlpha] uses dishonest and sometimes outright fraudulent ads along with deceptive websites to trick consumers into providing their personal information in exchange for a health insurance 'quote.' [MediaAlpha] then sells this information as raw lead data or uses it to generate clicks or calls for its lead-buying partners. Our investigation indicates as much as 78% of [MediaAlpha's] Health [Insurance] lead-buying partners are running boiler room health insurance scams or are flagrantly violating laws concerning telemarketing."

On this news, MediaAlpha's stock price fell $1.92 per share, or 11.84%, over the following two trading sessions, to close at $14.29 per share on June 25, 2024.

Then, on November 4, 2024, MediaAlpha disclosed receipt of a letter from the Federal Trade Commission ("FTC") staff stating that the FTC staff was "prepared to recommend the filing of a complaint against the Company," claiming that MediaAlpha falsely "represented itself as affiliated with government entities, made misleading claims (in particular regarding health insurance products and use of consumers' personal information) and utilized deceptive advertising."

On this news, MediaAlpha's stock price fell $4.46 per share, of 27.7%, to close at $11.62 per share on November 5, 2024.

Then, on August 6, 2025, MediaAlpha announced it was settling claims with the FTC for $45 million. According to the FTC's complaint, MediaAlpha would use advertisements and websites claiming to provide health insurance quotes to collect information from consumers looking for insurance, while in reality, MediaAlpha sold nothing to consumers, and the consumer information it collected would be sold to telemarketers. According to the FTC, MediaAlpha sold approximately 119 million leads about consumers in 2024 alone.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Freeport-McMoran Inc. - FCX

stocknewsapi

FCX

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Freeport-McMoran Inc. ("Freeport" or the "Company") (NYSE: FCX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Freeport and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On September 9, 2025, Freeport issued a press release announcing the suspension of mining activities at its Grasberg Block Cave operation in Indonesia, after "a large flow of wet material from a production drawpoint . . . blocked access to certain areas within the mine," trapping seven workers.

On this news, Freeport's stock price fell $2.80 per share, or 5.99%, to close at $43.87 per share on September 9, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RCI Hospitality Holdings, Inc. - RICK

stocknewsapi

RICK

NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RCI Hospitality Holdings, Inc. ("RCI" or the "Company") (NASDAQ: RICK).

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO

stocknewsapi

NVO

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Novo Nordisk and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until September 30, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Novo Nordisk securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com .

[Click here for information about joining the class action]

On July 29, 2025, Novo Nordisk significantly lowered its sales outlook for 2025. The Company attributed the reduction to "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition."

On this news, Novo Nordisk's American Depositary Receipt ("ADR") price fell $15.06 per ADR, or 21.83%, to close at $53.94 per ADR on July 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tronox Holdings Plc of Class Action Lawsuit and Upcoming Deadlines - TROX

stocknewsapi

TROX

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tronox Holdings Plc ("Tronox" or the "Company") (NYSE: TROX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Tronox and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 3, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Tronox securities during the Class Period. A copy of the Complaint can be obtained a t www.pomerantzlaw.com .

[Click here for information about joining the class action]

On July 30, 2025, Tronox announced its financial results for the second quarter of fiscal 2025, revealing a significant reduction in sales of the Company's TiO2 products for the quarter. The Company attributed the decline to "softer than anticipated coatings season and heightened competitive dynamics." As a result of the setback in sales, Tronox revised its 2025 financial outlook, lowering its full-year revenue guidance and reducing its dividend by 60%.

On this news, Tronox's stock price fell $1.95 per share, or 37.94%, to close at $3.19 per share on July 31, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in SelectQuote, Inc. of Class Action Lawsuit and Upcoming Deadlines - SLQT

stocknewsapi

SLQT

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against SelectQuote, Inc. ("SelectQuote" or the "Company") (NYSE: SLQT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether SelectQuote and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 10, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired SelectQuote securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com .

[Click here for information about joining the class action]

On May 1, 2025, the U.S. Department of Justice ("DOJ") filed a False Claims Act complaint against SelectQuote, alleging "[f]rom 2016 through at least 2021" SelectQuote received "tens of millions of dollars" in "illegal kickbacks" from health insurance companies in exchange for steering Medicare beneficiaries to enroll in the insurers' plans. Further, according to the DOJ, SelectQuote, in exchange for kickbacks, engaged in a conspiracy with major insurers to illegally discriminate against beneficiaries deemed to be less profitable, including those with disabilities. The DOJ concluded that SelectQuote made materially false claims by stating it offers "unbiased coverage comparisons" when in fact it "repeatedly directed Medicare beneficiaries to the plans offered by insurers that paid them the most money, regardless of the quality or suitability of the insurers' plans."

On this news, SelectQuote's stock price fell $0.61 per share, or 19.24%, to close at $2.56 per share on May 1, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lineage, Inc.- LINE

stocknewsapi

LINE

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lineage, Inc. ("Lineage" or the "Company") (NASDAQ: LINE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Lineage and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On or around July 25, 2024, Lineage conducted its initial public offering of 56,882,051 shares of common stock priced at $78.00 per share. Then, on April 30, 2025, Lineage reported its financial results for the first quarter of 2025. Among other items, Lineage reported that its total revenue had decreased by 2.7% to $1.29 billion for the quarter, stating that it "experienced more normal seasonal trends in the first quarter after multiple years of elevated inventory levels."

On this news, Lineage's stock price fell $8.26 per share, or 14.62%, to close at $48.23 per share on April 30, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Fly-E Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - FLYE

stocknewsapi

FLYE

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fly-E Group, Inc. ("Fly-E" or the "Company") (NASDAQ: FLYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Fly-E and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 7, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Fly-E securities during the Class Period. A copy of the Complaint can be obtained a t www.pomerantzlaw.com .

[Click here for information about joining the class action]

On August 14, 2025, Fly-E filed a form NT 10-Q: Notification of inability to timely file Form 10-Q for the first quarter of fiscal year 2026 revealing a substantial decrease of 32% in net revenues "primarily driven by a decrease in total units sold." In pertinent part, the Company attributed the decline to "recent lithium-battery accidents involving E-Bikes and E-Scooters."

On this news, Fly-E's stock price fell $6.76 per share, or 87.11%, to close at $1.00 per share on August 15, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines - CYTK

stocknewsapi

CYTK

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate ("Cytokinetics" or the "Company") (NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Cytokinetics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 17, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Cytokinetics securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com .        

[Click here for information about joining the class action]

On March 10, 2025, Cytokinetics disclosed that the U.S. Food and Drug Administration ("FDA") had decided not to convene an advisory committee meeting to review the Company's New Drug Application ("NDA") for aficamten. On May 1, 2025, Cytokinetics announced that the FDA had extended the Prescription Drug User Fee Act action date for aficamten's NDA from September 26, 2025 to December 26, 2025 in order to review a Risk Evaluation and Mitigation Strategy ("REMS") submitted at the FDA's request after the initial NDA filing, thereby disclosing that the Company had not included a REMS in the original NDA.

On this news, Cytokinetics' stock price fell $5.57 per share, or 12.98%, to close at $37.35 per share on May 2, 2025.

Then, on May 6, 2025, Chief Executive Officer Robert I. Blum acknowledged that Cytokinetics had multiple pre-NDA meetings with the FDA to discuss safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials.

On this news, Cytokinetics' stock price fell $2.70 per share, or 7.36%, to close at $33.97 per share on May 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Lantheus Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - LNTH

stocknewsapi

LNTH

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Lantheus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 10, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Lantheus securities during the Class Period. A copy of the Complaint can be obtained a t www.pomerantzlaw.com .

[Click here for information about joining the class action]

On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025, which fell short of market expectations. Lantheus announced, among other items, that sales of its radiopharmaceutical oncology product Pylarify had decreased year-over-year due to an alleged "temporal competitive disruption." The Company further reduced its previous full-year projections due to Pylarify's shortfall.

On this news, Lantheus's stock price fell $24.35 per share, or 23.23%, to close at $80.49 per share on May 7, 2025.

Then, on August 6, 2026, Lantheus announced disappointing second quarter 2025 results, revealing earnings-per-share ("EPS") and revenue figures that missed expectations. Once again, Lantheus significantly lowered growth expectations for Pylarify, sales of which had fallen 8.3% year-over-year, and further lowered the Company's full-year 2025 projections. Lantheus attributed its results in part to ongoing competition, which impacted Pylarify's pricing dynamics.

On this news, Lantheus's stock price fell $20.76 per share, or 28.58%, to close at $51.87 per share on August 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

Pomerantz Law Firm Announces the Filing of a Class Action Against Dow Inc. and Certain Officers - DOW

stocknewsapi

DOW

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Dow Inc. ("Dow" or the "Company") (NYSE: DOW) and certain officers. The class action, filed in the United States District Court for the Eastern District of Michigan, Northern Division, and docketed under 25-cv-12744, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Dow securities between January 30, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Dow securities during the Class Period, you have until October 28, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Dow is an American materials science company, serving customers in the packaging, infrastructure, mobility, and consumer applications industries. Dow conducts its worldwide operations through six global businesses organized into three operating segments: (i) Packaging & Specialty Plastics, (ii) Industrial Intermediates & Infrastructure, and (iii) Performance Materials & Coatings.

Historically, Dow has touted its "industry-leading dividend," which is of particular importance to investors. On conference calls with investors and analysts, Dow's Chief Executive Officer, Defendant Jim Fitterling ("Fitterling"), has variously stated that the Company's "dividend is a key element of our investment thesis," and that "north of 65% of our owners count on that dividend."

Notwithstanding an ongoing slump in the materials science industry, as well as the recent onset of tariff-related market uncertainties, at all relevant times, Defendants represented that Dow was well positioned to weather macroeconomic and tariff-related headwinds while maintaining sufficient levels of financial flexibility to support the Company's lucrative dividend. Specifically, Defendants cited various purported strengths and advantages unique to Dow in its industry, including, inter alia, the Company's purported "differentiated portfolio," "cost-advantaged footprint," and "industry-leading flexibility to navigate global trade dynamics."

Throughout the Class Period, Defendants made materially false and misleading statements regarding Dow's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Dow's ability to mitigate macroeconomic and tariff-related headwinds, as well as to maintain the financial flexibility needed to support its lucrative dividend, was overstated; (ii) the true scope and severity of the foregoing headwinds' negative impacts on Dow's business and financial condition was understated, particularly with respect to competitive and pricing pressures, softening global sales and demand for the Company's products, and an oversupply of products in the Company's global markets; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On June 23, 2025, BMO Capital downgraded its recommendation on Dow to "Underperform" from "Market Perform" while also cutting its price target on the Company's stock to $22.00 per share from $29.00 per share, citing sustained weakness across key end markets and mounting pressure on the Company's dividend.

On this news, Dow's stock price fell $0.89 per share, or 3.21%, to close at $26.87 per share on June 23, 2025.

Then, on July 24, 2025, Dow issued a press release reporting its financial results for the second quarter of 2025. Therein, Dow reported a non-GAAP loss per share of $0.42, significantly larger than the approximate $0.17 to $0.18 per share loss expected by analysts. Dow also reported net sales of $10.1 billion, representing a 7.3% year-over-year decline and missing consensus estimates by $130 million, "reflecting declines in all operating segments." The Company further reported, inter alia, that "[s]equentially, net sales were down 3%, as seasonally higher demand in Performance Materials & Coatings was more than offset by declines across the other operating segments." Defendant Fitterling blamed these disappointing results on "the lower-for-longer earnings environment that our industry is facing, amplified by recent trade and tariff uncertainties," while providing a dour outlook marked by "signs of oversupply from newer market entrants who are exporting to various regions at anti-competitive economics."

In a separate press release issued the same day, Dow revealed that it was cutting its dividend in half, from $0.70 per share to only $0.35 per share, citing the need for "financial flexibility amidst a persistently challenging macroeconomic environment."

Following these disclosures, Dow's stock price fell $5.30 per share, or 17.45%, to close at $25.07 per share on July 24, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 14:05 3mo ago

2025-09-28 10:00 3mo ago

Pomerantz Law Firm Announces the Filing of a Class Action Against Nutex Health Inc. and Certain Officers - NUTX

stocknewsapi

NUTX

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nutex Health Inc. ("Nutex" or the "Company") (NASDAQ: NUTX) and certain officers. The class action, filed in the United States District Court for the Southern District of Texas, and docketed under 25-cv- 03999, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nutex securities between August 8, 2024 and August 14, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Nutex securities during the Class Period, you have until October 21, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Nutex is a physician-led, healthcare services and operations company that began publicly trading via a reverse merger in April 2022. The Company operates through three divisions: a hospital division comprised of 24 hospital facilities in 11 states, a population health management division, and real estate. Nutex generally operates as an out-of-‎network provider and generates revenue, in part, from contracts with patients and, in most cases, a third-party payor such as commercial insurance, workers compensation insurance or, in limited cases, Medicare or Medicaid. According to Nutex, on average, greater than 90% of its net patient service revenue is paid by third-party payors.

Prior to 2022, if a patient with health insurance received care from an out-of-network provider, even unknowingly, the patient's health plan might not have covered the entire out-of-network cost, leaving the patient with higher costs than if the care had come from an in-network provider. In addition to any out-of-network cost sharing the patient might have owed, the out-of-network provider could bill the patient for the difference between the billed charge and the amount the patient's health plan paid, unless banned by state law—a practice called "balance billing". An unexpected balance bill from an out-of-network provider is frequently referred to as a "surprise bill".

In December 2020, to curb surprise out-of-network billing, Congress enacted the No Surprises Act ("NSA"). The NSA, which took effect January 1, 2022, requires private health plans to cover out-of-network claims and apply in-network cost sharing, and prohibits doctors, hospitals, and other covered providers from billing patients more than the in-network cost sharing amount for surprise medical bills. In addition, the NSA established an independent dispute resolution ("IDR") process to determine out-of-network payment amounts between health plans and providers when open negotiations fail to result in an agreed-upon payment amount.

In the IDR process, the provider and health plan each submit a proposed payment amount and ‎‎additional information supporting their payment offers to an arbitrator, a certified IDR entity. The arbitrator must select one of the two proposed payment amounts, taking into ‎account the ‎‎"qualifying payment amount" ("QPA")—the median contract rate for like specialties in the same geographical market—and additional circumstances including, among other things, the level of training, outcomes ‎‎measurements of the facility, the acuity of the individual treated, and the case mix and scope of services of the ‎facility ‎providing the service.

Initially, as an out-of-network provider, Nutex's business suffered after the NSA went into effect. Specifically, because cost sharing under the statute is generally based on the median in-network rate a health plan pays for a service, the NSA prevented Nutex from charging patients higher prices for its services through out-of-network billing. Indeed, in March 2023, Nutex reported that "[s]ince the NSA became effective [. . .] our average payment by insurers of patient claims for emergency services has declined by approximately 30% including as much as a 37% reduction for physician services." The Company stated that, "[i]n our experience, insurers often initially pay amounts lower than the QPA without regard for other information relevant to the claim. This requires us to make appeals using the IDR process."

In response, in July 2024, the Company engaged with HaloMD, a "third-party IDR vendor," to "assist in the recovery of certain out of network claims" in the IDR process. While Nutex did not disclose the identity of its third-party IDR vendor to investors at that time, the Company shortly thereafter began to tout the success of its "arbitration strategy" in increasing its revenues. For example, in August 2024, Nutex stated that it "believe[s] [] there is a lot of potential incremental value and revenue to be gained from arbitration" and "[i]n recent articles and public data, we are seeing that providers are prevailing 70% to 80% of the time in arbitration." Then, in March 2025, announcing its fourth quarter and full year 2024 results, Nutex reported that "[t]otal revenue increased $232.3 million to $479.9 million for the year ended December 31, 2024" and that "[t]he arbitration process resulted in approximately $169.7 million more in revenue in 2024 than in 2023, which amounted to approximately 73.1% of the $232.3 million revenue increase."

At all relevant times, the Company has identified material weaknesses in its internal control over financial reporting. Specifically, Nutex has acknowledged that it had "[i]neffective design, implementation, and operation controls over logical access, program change management, and vendor management controls," that "[b]usiness process controls across all financial reporting processes were not effectively designed and implemented to properly address the risk of material misstatement, including controls without proper segregation of duties between preparer and reviewer and key management review controls," and "[i]neffective design and implementation of controls over the completeness and accuracy of information included in key spreadsheets supporting the financial statements." However, Nutex has consistently represented that it has "started the process of designing and implementing effective internal control measures to remediate the reported material weaknesses."

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iv) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (v) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (vi) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the United States Securities and Exchange Commission ("SEC"); (vii) accordingly, Nutex's business and/or financial prospects were overstated; and (viii) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On July 22, 2025, Blue Orca Capital ("Blue Orca") issued a short report on Nutex (the "Blue Orca Report" or the "Report"). The Blue Orca Report alleged, among other things, that "HaloMD achieved dramatically lucrative results for clients like Nutex by engaging in a coordinated fraudulent scheme to steal millions of dollars from insurance companies on behalf of and in conjunction with its healthcare billing clients."

Specifically, Blue Orca referenced three recent "[b]ombshell [l]awsuits" filed against HaloMD. The lawsuits, brought variously by Blue Cross Blue Shield Healthcare Plan of Georgia, Inc., Community Insurance Company d/b/a Anthem Blue Cross and Blue Shield, and Anthem Blue Cross Life and Health Insurance Company and Blue Cross of California d/b/a Anthem Blue Cross, allege that HaloMD violated various federal and state laws by submitting false attestations of eligibility and initiating massive volumes of IDR disputes.

As summarized by Blue Orca, the plaintiffs in these lawsuits accused HaloMD and its clients of "flooding the arbitration system with thousands of claims that they knew at the time of submission to be ineligible" and alleging that HaloMD was able to garner improper payments by "falsely attesting to the eligibility of claims and [. . .] improperly inflating payment offers that far exceeded the amounts to which providers should have been entitled." Accordingly, Blue Orca concluded that "it may just be a matter of time before another suit is filed against HaloMD, this time including Nutex," and "[o]nce Nutex can no longer use the NSA arbitration system to receive unsustainably high reimbursement rates, our suspicion is that Nutex will return to penny stock status."

Following publication of the Blue Orca Report, Nutex's stock price fell $11.18 per share, or 10.05%, to close at $100.01 per share on July 22, 2025.

On July 24, 2025, Nutex issued a press release responding to the Blue Orca Report, stating that it "strongly disagrees with the allegations in the report" and that it "expects to provide related updates in its upcoming earnings release and Form 10-Q for the second quarter of 2025 due on or before August 14, 2025."

However, after the market closed on August 14, 2025, Nutex announced that it would "delay filing its Form 10-Q for the period ending June 30, 2025", citing "non-cash accounting adjustments related to the treatment of stock-based compensation obligations for certain under-construction and ramping hospitals, as disclosed in previous filings."

When Nutex failed to rebut the allegations of the Blue Orca Report, the Company's stock price fell $18.22 per share, or 16.39%, to close at $92.91 per share on August 15, 2025.

After the end of the Class Period, on August 21, 2025, Nutex filed a Current Report on Form 8-K with the SEC which, among other things, contained a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard and stated that the Audit Committee of the Company's Board of Directors concluded that certain of the Company's previously issued financial statements "treated non-cash obligations related to under-construction and ramping hospitals as equity rather than liabilities and should be restated." This filing also purported to address the Blue Orca Report. However, Nutex merely provided a generalized description of the arbitration process under the NSA and the Company's own claims process, acknowledged that Nutex had engaged HaloMD to assist in the IDR process, and discussed two of the three recent lawsuits filed against HaloMD, noting that the Company had not been named as a Defendant. As such, Nutex's filing did not in fact meaningfully rebut any of the allegations contained in the Blue Orca Report.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

2025-09-28 13:05 3mo ago

2025-09-28 07:30 3mo ago

Latam Insights: Venezuela Embraces USDT, OranjeBTC Rises in Brazil

cryptonews

USDT

Welcome to Latam Insights, a compilation of the most relevant crypto news from Latin America over the past week. In this week's edition: Venezuela moves its internal disbursements to USDT, OranjeBTC surges as Latam's largest bitcoin treasury company, and Argentina negotiates $20 billion lifeline with the U.S.

2025-09-28 13:05 3mo ago

2025-09-28 07:30 3mo ago

Hyperliquid's HyperDrive DeFi Loses $773K in Account Compromise, Funds Bridged to BNB Chain and Ethereum

cryptonews

BNB ETH HYPE

HyperDrive DeFi protocol suffered a $773,000 exploit affecting two accounts in its Treasury Bill market with stolen funds split between BNB Chain and Ethereum networks through bridge transfers, as the attacker exploited an arbitrary call vulnerability in the router contract stealing 672,934 USDT0 and 110,244 thBILL tokens.